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ABSTRACT 
Lee Kyung Hong: CD30-Redirected Chimeric Antigen Receptor T Cells Target Embryonal Carcinoma 
via Antigen-dependent and Fas/FasL Interactions 
(Under the direction of Gianpietro Dotti) 
 
 Embryonal carcinomas (ECs) and mixed testicular germ cell tumors (TGCTs) containing EC 
express CD30 and are the most aggressive TGCT subtypes. Chimeric antigen receptor T cells (CAR-Ts) 
combine the cytotoxic properties of T cells with the antigen specificity of monoclonal antibodies to target 
antigen-expressing cells, such as infected or cancerous cells. CAR-Ts targeting CD30 (CD30.CAR-Ts) 
have shown robust anti-tumor activity against Hodgkin’s lymphoma, but have not been tested against 
solid tumors. We tested whether CD30.CAR-Ts could also target ECs using in vitro and in vivo models. 
CD30.CAR-Ts exhibited anti-tumor activity in vitro against the human EC cell lines Tera-1, Tera-2 and 
NCCIT, and putative EC stem cells identified by Hoechst dye staining. Cytolytic activity of CD30.CAR-
Ts was complemented by sustained proliferation and pro-inflammatory cytokine production. CD30.CAR-
Ts also demonstrated anti-tumor activity in an in vivo xenograft NSG mouse model of metastatic EC. 
Remarkably, we observed that CD30.CAR-Ts, while targeting CD30+ EC tumor cells through the CAR 
(i.e. antigen-dependent targeting), also eliminated surrounding CD30– EC cells in an antigen-independent 
manner via cell-cell contact-dependent Fas/FasL interaction. In addition, inducing Fas (CD95) expression 
in CD30+ but Fas– EC was sufficient to improve CD30.CAR-T anti-tumor activity. Overall, these data 
suggest that CD30.CAR-Ts can be used as a novel immunotherapy for ECs. Additionally, Fas/FasL 
interaction between tumor cells and CAR-Ts can be exploited to reduce tumor escape due to 
heterogeneous antigen expression or to improve CAR-T anti-tumor activity. 
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CHAPTER 1: INTRODUCTION 
 Boosting the immune system to kill cancer cells has a more than 100-year history, beginning in 
1891 when William Coley, upon observing that cancer patients with infections showed better tumor control, 
used a mixture of heat-killed bacteria to induce regression of inoperable sarcomas (1). Adoptive T cell 
therapy harnesses the properties of cytotoxic T lymphocytes (CTLs), an arm of the adaptive immune 
system, to circulate systemically, migrate, and target unwanted cells such as infected and/or cancerous cells 
while sparing normal cells. As “living drugs,” T cells have multiple advantages over conventional therapies 
such as the ability to a) mount a specific cytotoxic immune response against target cells which can involve 
recruitment of other immune cells, b) proliferate in response to antigen stimulation, and c) survive long-
term in vivo (1). T cell therapies against solid tumors, which pose their own unique challenges compared 
to hematological malignancies, have been tested in clinical trials over the past thirty years with varying 
success. Here, advances in adoptive T cell therapy and the evolution of chimeric antigen receptor T cells 
(CAR-Ts) against solid tumors, with an emphasis on CD30-specific CAR-Ts, will be discussed. 
1.1 Tumor infiltrating lymphocyte (TIL) therapy for solid tumors 
Tumor infiltrating lymphocytes (TILs) were first described in the 1970s as potentially being 
associated with favorable prognosis as a consequence of increased immune surveillance (2;3). Further 
evidence that TILs had a T cell phenotype and the presence of HLA in breast cancer (4;5), melanoma (6;7) 
and renal cell carcinoma (8) suggested that, rather than playing a passive role, TILs exhibited anti-tumor 
activity mediated by a robust and specific immune response against the cancer cells. Indeed, more recent 
studies in ovarian cancer (9), colorectal cancer (10), breast cancer (11), and melanoma (12) have supported 
the overarching hypothesis in the immunotherapy field that TILs with an activated pro-inflammatory 
phenotype directly contribute to tumor cell lysis and an overall favorable clinical response. 
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Early clinical trials using TILs for melanoma showed promising results with 60% objective 
response (12;13), but relied on the use of recombinant IL-2 to expand TIL numbers in vitro after isolation 
from tumor biopsies. These protocols were further modified, for example by continuous administration of 
recombinant IL-2 (14), lymphodepletion prior to TIL infusion (15-17), or more recently using short-term 
cultured TILs (18) to further improve TIL expansion and persistence after infusion in patients. Based on 
these early results for melanoma, TIL clinical trials were subsequently expanded for other cancers. For 
renal cell carcinoma, TIL therapy with recombinant IL-2 showed a 9.1% complete response and 25.5% 
partial response (19). In addition, 29% of patients who received TILs with continuous infusions of IL-2 
showed an objective tumor response (14). Stage III non-small cell lung carcinoma patients (20) and 
epithelial ovarian cancer patients (21) also showed an improvement in reduced local relapse and improved 
disease-free survival compared to standard chemotherapy alone. 
However, many hurdles remained for TIL therapy that limited its applicability. Only a fraction of 
cancer patients qualified for TIL therapy based on several criteria: a) a resectable tumor that is TIL positive, 
b) TILs that can be successfully isolated and expanded, and c) TILs that exhibit anti-tumor activity (22).  
Because of the high number of TILs required (on the order of 1010-11), in vitro expansion was laborious and 
took several weeks (23;24) and was not feasible for some TILs (25). In addition, whether TILs contain 
tumor specific CTLs was difficult to test due to limited numbers of TILs and the requirement for fresh 
viable autologous and allogeneic tumor cells for screening purposes. Several studies even showed mixed 
results or little benefit of TIL therapy (8;26;27). Subsequently, engineered T cells containing either T cell 
receptors (TCRs) or chimeric antigen receptors (CARs) were tested to develop an adoptive T cell therapy 
that used lower T cell numbers while maintaining tumor antigen specificity. 
1.2 Engineered T cell receptor (TCR) T cell therapy for solid tumors 
 TILs have a limited T cell receptor (TCR) beta-chain variable region usage (28;29), suggesting that 
selecting for or engineering TCRs against tumor-associated antigens could be an alternative approach to 
generating sufficient T cell numbers with pre-defined functional avidity. This approach would significantly 
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shorten the manufacturing process compared to TILs, which require higher T cell numbers. Engineered 
TCRs can also recognize both extracellular and intracellular targets that are MHC-presented, thus 
broadening the scope of tumor-associated antigens to target compared to CARs, which only recognize 
extracellular antigens.  
Morgan et al (30) published the first report of MART-1 TCR T cells mediating tumor regression. 
Subsequent studies combining MART-1 TCR T cells with dendritic cell vaccination resulted in tumor 
regression among 69% of participants (31). TCR T cells against other melanoma antigens such as gp100 
(32) and NY-ESO-1 (33) showed promising results, though these trials had small cohorts. NY-ESO-1 TCR 
T cells, in particular, have been further tested in multiple myeloma with 50% progression-free survival (34) 
and synovial cell sarcoma with 61% objective response (33;35). Other tumor-associated antigens such as 
CEA (36) and cancer testis antigens MAGE-A3 (37;38) and MAGE-A4 (39) have been targeted using TCR 
T cell therapy. 
However, there are several limitations to engineered TCRs. First, the number of patients who can 
benefit from TCR therapy is limited based on HLA haplotype (40). TCR affinity for cancer targets, as 
opposed to viral peptides, is typically in the low micromolar range since many tumor-associated antigens 
are derived from self antigens (41); this low affinity can further limit the activation and cytotoxicity of 
engineered TCR T cells. In addition, new unintended specificities may derive from mispairing with 
endogenous chains or as consequence of artificial enhancement of affinity (42;43). Finally, tumor cells can 
escape TCR T cell targeting by downregulating HLA expression (44). An alternative approach, which does 
not rely on HLA expression and antigen presentation, was also needed. 
1.3 Chimeric antigen receptor (CAR) T cell therapy for solid tumors 
Chimeric antigen receptors (CARs) are designed based on endogenous T cell activation through 
the TCR (Fig.1A), which requires engagement of the extracellular receptor with its cognate antigen 
presented on HLA in order to induce downstream signal transduction through the CD3ζ endodomain. CARs 
were first described by Gross and colleagues (45), who replaced the Vα and Vβ extracellular domains of 
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the TCR with heavy and light chain Fv domains. They showed that the chimeric receptor endowed T cells 
with the ability to recognize its target antigen in a non-MHC restricted manner and induced T cell activation 
and IL-2 production. Chimeric antigen receptor T cells (CAR-Ts), unlike engineered TCR T cells, do not 
rely on pairing for proper activation through the receptor. Instead, the extracellular single-chain variable 
fragment (scFv) of the CAR recognizes the target antigen in a MHC-independent manner and with higher 
affinity than TCRs (46). 
Over its 20-plus year history, CARs have undergone several major modifications to improve its 
function (Fig.1B). The first major milestone in CAR development was when Zelig Eshhar and colleagues 
fused a scFv to a transmembrane domain and intracellular CD3ζ endodomain, called the T-body or first-
generation CAR (47). Eshhar’s group subsequently showed CAR-T lytic activity against ovarian cancer 
cell lines (48), Neu/HER2 expressing transformed cells (49), and B cell lymphomas (50). However, these 
first-generation CARs were unable to activate resting or naïve T lymphocytes, and CAR-Ts produced 
limited amounts of cytokines (51). Second-generation CARs integrated endodomains from co-stimulatory 
molecules traditionally provided as “signal 2” of TCR-mediated activation, such as CD28 (52), ICOS (53), 
CD134 (OX40R) (54), and CD137 (4-1BB) (55) to further enhance T cell proliferation and cytokine 
production. CAR-Ts have also been further engineered to express cytokines or co-stimulatory ligands to 
further support their proliferation and/or migration to tumor sites (56). 
CARs used today are comprised of series of domains: an extracellular domain that recognizes a 
target antigen, a hinge/spacer domain to extend the extracellular domain from the cell surface, a 
transmembrane domain, and endodomain(s). The extracellular domain contains the antigen-binding 
domain, most commonly derived from a scFv of a monoclonal antibody (mAb), along with a hinge/spacer 
domain derived from immunoglobulin-like CH2-CH3 (Fc) domains of immunoglobulin G (IgG), CD8α, or 
CD28 (57). The optimal length of the spacer domain is empirically determined depending on the target 
antigen (46), sometimes directly affecting the affinity of CAR-Ts to their target antigen (58). The 
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endodomain transmits T cell signals to induce activation in a similar manner to TCR-mediated activation 
(47).  
Early pre-clinical models showed promising improvements (52;54), and were more specifically 
designed against solid tumor antigens prostate-specific membrane antigen (PSMA) (59) and CEA (60), or 
the leukemia/lymphoma antigen CD19 which is the most commonly studied CAR to date (55;61-63). Third-
generation CARs, which incorporate an additional co-stimulatory molecule, showed enhanced cytokine 
production, sustained proliferation, and better tumor control in vivo compared to either co-stimulatory 
molecule alone (64-66), but clinical experience with third-generation CARs is limited (67). CAR-Ts have 
been further engineered to express cytokines or co-stimulatory ligands to further improve T cell persistence, 
homing, and anti-tumor activity in vivo, or “armored” CARs (56). 
Clinical trials using CAR-Ts for solid tumors have also had mixed results. Perhaps not surprisingly, 
initial clinical trials with first-generation CAR-Ts, such as the CD171 CAR for neuroblastoma (68) and 
CAIX CAR for metastatic renal cell carcinoma (69) showed limited CAR-T persistence after infusion. 
Another first-generation CAR-T targeting folate receptor alpha for ovarian cancer showed successful 
engraftment but poor anti-tumor efficacy (70). Second-generation CAR-Ts against EGFR variant III 
(EGFRvIII) (71;72) and IL13Rα2 (73) are under active investigation for glioblastoma (GBM). In addition 
to targeting protein antigens, investigators have developed CAR-Ts against a cancer-specific glycoform of 
MUC-1 for metastatic seminal vesicle cancer (74). Others have focused on targeting tumor stroma, such as 
fibroblast associated protein (FAP) CAR-T cells (75) with clinical trials ongoing for mesothelioma, or 
targeting vasculature (VEGFR-2) associated with tumor angiogenesis (76). The most promising clinical 
outcomes to date have been in HER2-specific CAR-Ts for sarcoma (77) in which 4 out of 19 subjects 
achieved stable disease, GD2 CAR-Ts for neuroblastoma with 3 out of 11 in complete remission (78), and 
HER1 CAR-Ts for lung cancer showing partial response in 2 out of 11 subjects (79). Overall, the use of 
TILs, engineered TCRs, and CARs has shown some advantages and disadvantages related to the design and 
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manufacturing process, as well as to target antigens. A comparison between these adoptive T cell therapies 
is summarized in Table 1. 
1.4 Development of CD30-specific CAR-Ts (CD30.CAR-Ts) 
CD30 (encoded by TNFRSF8) is a member of the TNF receptor superfamily that was initially 
discovered in Reed-Sternberg cells of Hodgkin’s Lymphoma (HL) (80-83). Its extracellular domain can be 
cleaved to produce a soluble form, which can be released into the serum (84), but importantly antibody 
binding of CD30 is unaffected even in the presence of soluble CD30 (85). CD30 ligand (CD30L, or CD153), 
also a member of the TNF family, can be membrane-bound or soluble. Binding of CD30 with its ligand 
induces downstream signal transduction and activation of NF-kB (86); however, its function is variable 
depending on context and target cells. While CD30 function in normal cells like lymphocytes is unclear, 
CD30 has been shown to promote cell proliferation and survival in transformed embryonic stem cells (87).  
Because of its limited expression in normal tissues and high expression in Reed-Sternberg cells, 
CD30 has been targeted by multiple investigators using monoclonal antibodies. Initial studies were done in 
1992 using the anti-CD30 murine monoclonal antibody Ber-H2 and showed tumor localization but no anti-
tumor activity (88). Other CD30-targeting antibodies, such as Ber-H2 conjugated to the Saproin toxin 
(89;90) or human anti-CD30 monoclonal antibody (91) showed modest responses. Brentuximab vedotin 
(BV), an antibody-drug conjugate of an anti-CD30 antibody with a potent anti-microtubule cytotoxin 
monomethyl auristatin E (MMAE) (92), has shown the highest response rates to date for anti-CD30 
antibody therapy (93-95) and was subsequently approved by the FDA in 2011 for relapsed HL (84). 
At around the same time in the mid-1990s, a CD30 chimeric antigen receptor was being developed 
to engineer into T cells (CD30.CAR-T). The first-generation CD30.CAR-T consisted of an extracellular 
single-chain anti-CD30 antibody fragment and Fc-epsilon-I-gamma receptor signaling endodomain and 
showed specific lysis of CD30-expressing HL cell lines in vitro (85;96). Epstein-Barr-virus specific T cells 
transduced with a CD30.CAR also showed lytic activity against both autologous EBV+ HL cells through 
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the native TCR and EBV-CD30+ HL cells through the CAR (97). Importantly, although a subpopulation of 
activated T cells express CD30, CD30.CAR-Ts did not impair adaptive immune responses (97).  
Second-generation CD30.CAR-Ts incorporating the CD28 endodomain (56) have subsequently 
been tested in phase I clinical trials for CD30-expressing HL and anaplastic large-cell lymphoma (ALCL) 
patients without pre-conditioning chemotherapy, eight of whom had brentuximab-refractory disease, with 
one complete response and one partial response (98). In another phase I trial using CD30.CAR-Ts with the 
4-1BB endodomain, HL and ALCL patients with pre-conditioning chemotherapy showed a partial response 
in 7 out of 18 patients, and biopsied tissues showed CAR-T trafficking with reduction of tumor CD30 
expression (99). However, CD30.CAR-Ts have not yet been tested against solid tumors. In Chapter 2, I 
describe the novel use of CD30.CAR-Ts against embryonal carcinomas (ECs), a solid tumor, and 
specifically how Fas/FasL interactions between tumor and T cells contribute to elimination of both antigen-
positive and antigen-negative (bystander) tumor cells. Finally, in Chapter 3, I discuss the broader 
implications of targeting the Fas/FasL pathway and how to further improve CAR-T immunotherapy against 
solid tumors. 
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Figure 1.1: Chimeric antigen receptor (CAR) evolution. (A) Schematic of T cell receptor (TCR) 
signaling, which requires signal 1 (TCR engagement with its cognate peptide presented on MHC), signal 2 
(co-stimulation by CD28, 4-1BB, or other co-stimulatory molecules), and signal 3 (cytokine milieu) for 
optimal activation. (B) Schematic of CAR design, in chronological order from left to right showing 
incorporation of co-stimulatory domains (second- and third-generation CARs) as well as the addition of 
cytokine or co-stimulatory ligand expression by T cells (“armored” CAR). Adapted from (57). 
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 Pros Cons 
Tumor infiltrating lymphocytes 
(TILs) 
• Polyclonal repertoire 
enables targeting multiple 
antigens and potentially 
minimizes tumor escape 
• Likely enriched for T cell 
subsets that already show 
anti-tumor activity 
• Long manufacturing process 
(8-12 weeks) 
• Difficult to isolate (requires 
tumor biopsy and presence 
of TILs) 
Engineered T Cell Receptors 
(TCRs) 
• Target both extracellular 
and intracellular antigens 
presented on MHC 
• Can signal through TCR 
with as little as 1 MHC-
peptide complex present on 
target cells 
• Pre-defined antigen 
specificity 
• Limited to specific HLA 
haplotype 
• Tumor cells can escape by 
MHC downregulation 
• Relies on co-stimulation 
from target cells 
• Potential formation of 
mispaired TCRs with 
unintended specificities 
Engineered Chimeric Antigen 
Receptors (CARs) 
• Bypasses MHC restriction 
and co-stimulation 
• High affinity 
• Other non-protein antigens, 
such as glycoproteins and 
glycolipids, can be targeted 
• Pre-defined antigen 
specificity 
• Only extracellular antigens 
can be targeted 
• Requires sufficient number 
of antigens to initiate T cell 
activation 
• Immune response may be 
directed against the CAR 
(ex. HAMA), which can be 
minimized by using 
humanized scFvs 
Table 1.1: Comparison of Adoptive T Cell Therapies 
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CHAPTER 2: CD30.CAR-Ts TARGET EMBRYONAL CARCINOMA1 
2.1 Introduction 
Testicular germ cell tumors (TGCTs), sub-categorized as seminomas and non-seminomas (NS-
TGCTs), are the most common malignancies in male adolescents and young adults (100), and incidence 
continues to rise in the United States and worldwide (101). Pure embryonal carcinomas (EC), a subtype of 
NS-TGCTs derived from malignant embryonic stem cells, accounts for 2% of all TGCTs (102). More 
commonly, EC is a histologic component in 85% of mixed TGCTs in which multiple subtypes are present 
(102), and the presence of EC is associated with poor outcomes (103). While orchiectomy is curative in 
patients with localized (i.e. stage 1) NS-TGCTs (104), patients with metastatic disease and those 
presenting with primary mediastinal tumors, even when cured, often develop long-term chemotherapy-
related side effects that reduce their life expectancy (105). In addition, patients who relapse after 
chemotherapy have poor prognosis, with an overall survival rate of only 30-40% (106). Therefore, 
immunotherapy may be beneficial in improving overall survival while reducing chemotherapy-associated 
morbidities. 
CD30 antigen expression is a distinctive feature of ECs and an attractive target for 
immunotherapy (107). CD30 is a TNF superfamily member with a pro-survival role in transformed stem 
cells (87). Furthermore, CD30 is stably expressed by ECs at diagnosis and at relapse, and the persistence 
of CD30+ tumor cells post-chemotherapy is considered a negative prognostic factor (108). Targeting 
CD30 by brentuximab, a toxin-conjugated anti-CD30 monoclonal antibody (mAb), has led to partial 
responses in 2 out of 3 TGCT patients in a phase 2 open-label multicenter study (109). In a separate 
                                                           
1 Lee Kyung Hong, Yuhui Chen, Christof Chiu Smith, Stephanie Montgomery, Benjamin Vincent, Gianpietro Dotti, 
Barbara Savoldo 
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study, 22% of patients with mixed TGCTs treated with brentuximab achieved objective but transient 
clinical responses (110). 
Chimeric antigen receptor (CAR)-based technology overcomes some of the limitations of mAb-
based immunotherapy because CARs combine the antigen specificity of a mAb with intrinsic properties 
of T lymphocytes (111). CARs are chimeric proteins in which an Ab single-chain variable fragment 
(scFv), as an extracellular receptor, is fused with T cell effector and co-stimulatory intracellular domains 
(112). In sharp contrast to mAbs, CAR-expressing T lymphocytes (CAR-Ts) can persist long-term, 
migrate to the tumor site following chemokine gradients such as CXCL12 in TGCTs (103), and exploit 
multiple lytic functions (113). CD30-redirected CAR T cells (CD30.CAR-Ts) have shown anti-tumor 
activity in vitro and in vivo in preclinical lymphoma models (97;114), and more recently in patients with 
Hodgkin’s lymphomas and CD30+ non-Hodgkin’s lymphomas (98;99). However, CD30.CAR-Ts have 
not yet been explored in solid tumors. Here, we demonstrated the anti-tumor activity of CD30.CAR-Ts 
against CD30+ ECs and discovered a mechanistic link between the lytic activity of CD30.CAR-Ts against 
bystander CD30– ECs and the Fas/FasL pathway. Furthermore, we showed that inducing Fas expression 
in otherwise Fas– EC cells enhanced CD30.CAR-T-mediated tumor elimination. These results support the 
use of CD30.CAR-Ts as a novel form of immunotherapy for CD30+ TGCTs. 
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2.2 Methods 
Tumor cell lines. The Hodgkin’s lymphoma-derived cell line HDLM-2 was obtained from the 
German Collection of Cell Cultures (DMSZ, Braunschweig, Germany). The Burkitt’s lymphoma-derived 
cell line Raji, the EC-derived cell lines NCCIT, Tera-1, and Tera-2, the neuroblastoma-derived cell line 
Lan-1, and the leukemia-derived cell line K562 were obtained from American Type Culture Collection 
(ATCC). K562 cells were transduced with a retroviral vector encoding human CD19 to constitutively 
express CD19. Similarly, Lan-1 cells were transduced with a retroviral vector encoding human CD30 to 
constitutively express CD30. For CD95 overexpression in NCCIT cells, the full-length human CD95 was 
cloned into the retroviral vector PLX encoding the puromycin resistance gene. For CD95 knockdown in 
Tera-1 cells, we used the previously described CD95 siRNA pSUPER vectors (115). The retroviral vector 
encoding eGFP-Firefly-Luciferase (eGFP-FFLuc) was used to label either tumor cells or CD30.CAR-Ts 
for in vivo studies (56). Raji, K562, Lan-1 and NCCIT cells were maintained in culture with RPMI 1640 
medium (Gibco) supplemented with 10% fetal bovine serum (Corning), 1X penicillin-streptavidin 
(Invitrogen), and 2 mM GlutaMax (Invitrogen). Tera-1 and Tera-2 cells were maintained with McCoy’s 
5A media (Corning) with 15% FBS, 1X penicillin-streptavidin, and 2 mM GlutaMax. Cells were 
maintained in culture in a humidified atmosphere containing 5% CO2 at 37°C. Tumor cell lines were 
routinely tested to exclude contamination with mycoplasma and assessed for the expression of CD30 by 
flow cytometry to confirm identity. 
Retroviral constructs and transduction of T lymphocytes. We constructed two second-
generation CD30.CARs encoding either the CD28 (CD30.28) or 4-1BB (CD30.BB) endodomains 
coupled with the CD3ζ endodomain (Fig. S1A) using the previously reported CD30-specific single-chain 
variable fragment (scFv) (97). Non-transduced T cells from matched donors or T cells transduced with a 
CD19.CAR encoding the CD28 endodomain (63) were used as controls for in vitro and in vivo 
experiments, respectively. Transient retroviral supernatants were produced using 293T cells as previously 
described (56). Peripheral blood mononuclear cells isolated from buffy coats of healthy volunteer blood 
13 
 
donors (Gulf Coast Regional Blood Center, Houston, TX) were transduced to express the CD30.CARs or 
CD19.CAR and maintained in culture as previously described (116).  
Flow cytometry. The following mAbs conjugated with phycoerythrin (PE), fluorescein 
isothiocyanate (FITC), allophycocyanin (APC), APC-H7, Alexa Fluor 647 (AF 647), Alexa Fluor 700, 
Brilliant Violet (BV) 711, and/or peridinin chlorophyll protein (Per-CP) were used: CD3, CD4, CD8, 
CD30 (Clone Ber-H3), CD33, CD45, CD45RA, CD45RO, CD95, CCR7, Ganglioside GD2 (GD2) and 
active caspase 3 (BD Biosciences). Rabbit anti-cleaved caspase 7 and Alexa Fluor 488-conjugated goat 
anti-rabbit IgG mAbs were purchased from Cell Signaling Technologies. CAR expression by T cells was 
detected using a goat anti-mouse F(ab’)2 antibody (Jackson Immuno). To detect CD19.CAR we used a 
specific anti-idiotype antibody (Clone 233-4A) generated by immunizing mice with the anti-CD19 scFv 
followed by APC-conjugated rat anti-mouse IgG secondary mAb (BD Biosciences). For absolute number 
calculations, samples were analyzed using CountBright absolute counting beads per manufacturer’s 
instructions (Thermo Fisher). For intracellular staining, cells were stained with surface antibodies, then 
washed and fixed with Cytofix/Cytoperm (BD), followed by intracellular staining in 1X permeabilization 
buffer per manufacturer’s instructions. Samples were analyzed using a FACSCanto II flow cytometer 
(BD), and data were analyzed by FlowJo (Treestar). At least 10,000 positive events were collected for 
each sample. FACS sorting was also performed using CD30-PE or CD95-PE labeled tumor cells on an 
Aria III flow cytometer (BD; UNC Flow Cytometry Core Facility). 
Side Population (SP) staining by Hoechst dye/Dye Cycle Violet and cell sorting. For SP 
analysis, cells were incubated in HBSS (Life Technologies) containing 2% FBS, 10 mM HEPES (Life 
Technologies), and either 10 µg/mL Hoechst 33342 (Sigma-Aldrich) or 10 µM Vybrant DyeCycle Violet 
(DCV) (Life Technologies) for 90 min at 37°C. Cells were then washed with ice cold HBSS and FACS 
sorted or labeled with CD30-PE for flow cytometry analysis. To detect the SP fluorescent phenotype, 
Hoechst 33342 samples were excited using a 355nm UV laser on a LSRII/Fortessa flow cytometer (BD) 
while DCV samples were excited using a 405 nm violet laser on an Aria III flow cytometer. 
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Corresponding band-pass filter sets were: blue 450-50 bp/450 LP, 610-20 bp/690 LP (LSRII/Fortessa) 
and 450-50 bp/502 LP (Aria III).  
  Cytotoxicity assay. The cytotoxic activity of transduced effector cells was evaluated using a 6-
hour 51Cr release assay as previously described (16). Labeled target cells were: Raji (CD30–), HDLM-2 
(CD30+), Tera-2, and NCCIT. 
In vitro co-culture. Adherent tumor cell lines were plated at 0.1 - 0.25 × 106 cells/mL in a 24-
well tissue culture plate one day prior to the addition of CD30.CAR-Ts or CD19.CAR-Ts at various 
effector/target (E:T) ratios. After five days in culture at 37°C, cells were collected using Versene (UNC 
Tissue Culture Facility) for non-enzymatic dissociation of tumor cells, washed in PBS, labeled with 
fluorescent CD3-APCH7 and CD30-FITC mAbs and analyzed by flow cytometry. In experiments with 
Lan-1/WT or Lan-1/CD30 control tumor cells, remaining cells were labeled with CD3-APCH7 and GD2-
PE (Clone 14.G2a) mAbs. In experiments where CD19.CAR-Ts and K562 cells were used, remaining 
cells were also labeled with CD33-APC mAb. Transwell assays were performed using 0.4 μm transwells 
(EMD Millipore) in 24-well tissue culture plates. 
Carboxyfluorescein succinimidyl ester (CFSE)-based proliferation assay. CD30.CAR-Ts and 
control T cells were labeled with CFSE following manufacturer's instructions (Invitrogen) and co-
cultured with tumor cells at 5:1 E:T ratio. On day 5, cells were collected, labeled with CD3-APCH7, 
CD4-PECy7, and CD8-APC mAbs (BD Biosciences), and analyzed for CFSE dilution by flow cytometry. 
In separate co-culture experiments, tumor cells were labeled with CFSE and plated one day prior to the 
addition of control T cells and CD30.CAR-Ts. Five days later cells were collected and CFSE+ tumor cells 
were identified by flow cytometry. 
Enzyme-linked immunosorbent assay (ELISA). The release of IL-2 and IFNγ by CD30.CAR-
Ts was quantified using specific ELISAs (R&D Systems) in supernatants collected after 24 hours from T 
cells co-cultured with tumor cells. 
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Reverse transcription quantitative polymerase chain reaction. Cells were lysed and RNA was 
extracted using the RNeasy Mini kit (Qiagen) and reverse transcribed into cDNA (Superscript VILO, 
Invitrogen). Human ABCG2, SOX2, and CD95L (FasL) mRNA expression was quantified using Taqman 
probes (Applied Biosystems) on a Quantstudio 6 PCR machine (Applied Biosystems) using β-actin as 
housekeeping gene control (Invitrogen). 
Xenograft mouse models. To measure in vivo the growth of EC cells, we used two orthotopic 
models in 6–12 week-old NOD/SCID/γcnull (NSG) male mice. In the first model, Tera-2 eGFP-FFLuc 
cells were re-suspended in DPBS (Corning) and injected directly into the left testis (2 × 106 cells/mice) 
(117). In the second model, Tera-2 eGFP-FFLuc cells were re-suspended in Matrigel (Corning) and 
engrafted under the left kidney capsule (0.25 × 106 cells/mice) (118). To assess anti-tumor activity of 
CD30.CAR-Ts, mice received T cells (1 × 107 cells/mouse) intravenously via tail vein injection 14 days 
later, when the bioluminescence emission (BLI) of the tumor was consistently measurable. To monitor T 
cell localization and expansion, mice were engrafted with wild type (WT) Tera-2 cells, and infused 21 
days later with 1 × 107 control or CD30.CAR-Ts transduced with eGFP-FFLuc. The IVIS imaging system 
(Xenogen; UNC Biomedical Imaging Research Center) was used to monitor tumor growth or T cell 
expansion and localization. Briefly, a constant region of interest was drawn over the tumor regions and 
the intensity of the signal measured as total flux (photon/sec) as previously described (118). 
Mouse tissue processing and immunohistochemistry (IHC). T cell-treated mice with tumor 
engrafted in kidney or testis were sacrificed and tumors were fixed in 10% neutral buffered formalin 
(Fisher Scientific), processed in 3 μm longitudinal planes, and stained for hematoxylin/eosin (H&E) and 
anti-human CD3 mAb (UNC Lineberger Animal Histopathology Core Facility). Blood samples 
normalized to 100μL total volume and spleen samples were also harvested, lysed to remove red blood 
cells (ACK Lysis Buffer, Gibco), and stained with anti-human CD45 and CD3 for detection of T cells. 
For detection of CD30, mouse tissues and human testes tissue arrays (US Biomax) were stained with anti-
human CD30 mAb (Clone Ber-H2, Dako; UNC Translational Pathology Laboratory). H score is the 
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cumulative score of the frequency of positive cells x score calculated by a membrane staining algorithm, 
which scores cells based on membrane staining intensity, while the frequency of CD30+ cells is the 
percent total positive staining cells (UNC Translational Pathology Laboratory). Tumors collected from 
tumor bearing mice were counted by a board-certified veterinary pathologist (S. Montgomery) blinded to 
experimental conditions. A random tumor field containing at least 80% tumor and positively labeled CD3 
cells was selected and, depending on tumor size, up to ten high power (400X) fields of view were 
examined using a grid matrix approach as previously described (118). Two samples from mice treated 
with either CD30.28-Ts or CD30.BB-Ts had sheets of positive cells that were too numerous to count 
(TNTC) and were not included in the quantitative analysis. 
RNA-Seq. Briefly, total RNA was extracted from EC cell lines and mRNA libraries were 
prepared (TruSeq Stranded mRNA Library Prep, Illumina) and sequenced on the Illumina HiSeq4000 
platform (UNC High-Throughput Sequencing Facility) using paired-end 100-bp reads, with 84 million 
reads on average (range 49–139 million). RNA-seq data was aligned with STAR alignment (v2.4.2) and 
quantified with Salmon (v0.6.0). Differential gene expression analysis was performed using the R 
DESEq2 package (https://genomebiology.biomedcentral.com/articles/10.1186/s13059-014-0550-8).  
Among all significantly expressed genes between NCCIT, TERA1, and TERA2 cell lines (FDR p-value < 
=0.05), expression was further filtered to genes contained within the KEGG Apoptosis and the Biocarta 
p53 pathway signatures (https://www.ncbi.nlm.nih.gov/pubmed/10592173; 
https://doi.org/10.1089/152791601750294344).   
Statistical analysis. All in vitro data are presented as mean ± SEM. A two sided, paired Student’s 
T test was used to determine the statistical significance of differences between groups, and p-values less 
than .05 were accepted as indicating a significant difference. When multiple comparison analyses were 
required, statistical significance was evaluated by one-way ANOVA or repeated-measures ANOVA for 
matched donors followed by two-sided paired Student’s T test as needed for comparing two groups. 
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Statistical significance for differences in tumor growth in vivo were evaluated by one-way ANOVA. 
Differences in survival curves for mouse experiments were compared by log-rank (Mantel-Cox) test. 
Study approval. All mouse experiments were performed in accordance with University of North 
Carolina Animal Husbandry and Institutional Animal Care and Use Committee (IACUC) guidelines and 
were approved by UNC IACUC. 
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2.3 Results 
EC cell lines and TGCT tissue specimens express CD30. We assessed the expression of CD30 
in three human EC cell lines (Tera-1, Tera-2, and NCCIT) by flow cytometry, and used wild type Lan-1 
(Lan-1/WT) and CD30+ Lan-1 (Lan-1/CD30) cells as negative and positive controls, respectively. The 
HDLM-2 Hodgkin’s lymphoma cell line that constitutively expresses CD30 (119) was also used as a 
positive control. All EC cell lines expressed CD30 but also contained a fraction of CD30–/dim cells, which 
were more prominent in the Tera-1 cell line (Fig.2.1A). We next examined CD30 expression by 
immunohistochemistry (IHC) in human tissue microarrays (TMA) that include normal testes, seminomas, 
and NS-TGCTs. Normal testes and seminomas did not display CD30 staining (Fig.2.1B). In contrast, up 
to 70% of EC specimens exhibited a moderate to strong, granular, membranous and Golgi CD30 staining 
pattern (Fig.2.1B). When the pattern of CD30 expression was scored using computational analysis and 
analyzed as H score (Fig.2.1C) or as frequency of positive cells (Fig.2.1D), CD30 was routinely 
expressed only by primary ECs (p<0.001, one-way ANOVA), although with some heterogeneity. 
CD30.CAR-Ts target CD30+ EC cell lines and their side population (SP) cells. We 
engineered T cells to express either CD30.28 or CD30.BB CARs (Fig.2.S1A). Transduction efficiency 
was consistently >90% for both constructs (Fig.2.S1B), and CD30.CAR-Ts expanded in vitro in the 
presence of cytokines (Fig.2.S1C). CD30.CAR-Ts showed phenotypic characteristics of stem cell-like, 
effector-memory and central-memory T cells (Fig.2.S1D).  
CD30.CAR-Ts lysed CD30+ tumor cells at higher frequencies compared to control T cells 
(Ctr.Ts), while sparing CD30– tumor cells in short-term 51Cr release assays (Fig.2.2A). CD30.CAR-Ts 
also effectively eliminated CD30+ tumor cells in long-term co-culture experiments. Specifically, using 
effector:target (E:T) ratios ranging from 1:5 to 5:1, both CD30.28-Ts and CD30.BB-Ts exhibited anti-
tumor activity against all three EC cell lines tested (Fig.2.2B-D and 2.S2B-D). Of note, while 
CD30.CAR-Ts efficiently eliminated Tera-1 (Fig.2.2B and 2.S2B) and Tera-2 (Fig.2.2C and 2.S2C) cells 
at low E:T ratios (1:1, 1:2 and 1:5), they could only control NCCIT cell growth at the highest 5:1 E:T 
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ratio (Fig.2.2D). CD30.CAR-Ts targeted Lan-1/CD30 cells while neither Ctr.Ts nor CD30.CAR-Ts 
eliminated Lan-1/WT cells (Fig.2.S2A). Both CD30.28-Ts and CD30.BB-Ts showed robust proliferation 
in response to EC cells, as assessed by CFSE dilution assays (Fig.2.S3A), confirming both endodomains 
provided adequate co-stimulation. Additionally, CD30.CAR-Ts secreted IFNγ and IL-2 upon stimulation 
with EC cells (Fig.2.S3B,C). In summary, CD30.CAR-Ts showed selective activation by CD30+ EC cells 
and anti-tumor activity in vitro. 
Cancer stem cells are a subpopulation of tumor cells with stem cell characteristics that can 
contribute to tumor relapse (120). Taking in consideration the germinal origin of ECs, we examined if EC 
cell lines contain putative cancer stem cells using the Hoechst 33342 staining for detection of SP cells 
(121). While all EC lines had a proportion of SP cells, Tera-1 cells showed the highest frequency of SP 
cells (15-30%) (Fig.2.3A). SP cells retained the expression of CD30 (Fig.2.3A) and exhibited cancer stem 
cell characteristics based on the expression of the stem cell-associated markers ABCG2 (122) and SOX2 
(123) (Fig.2.3B), and their capacity to differentiate to non-SP cells (121) (Fig.2.3C). Importantly, 
CD30.CAR-Ts targeted sorted SP cells in co-culture assays (Fig.2.3D). Therefore, CD30.CAR-Ts can 
target both differentiated and stem cell-like CD30+ EC cells. 
CD30.CAR-Ts localize to EC tumors and exhibit anti-tumor activity in vivo. To model EC in 
vivo, we inoculated NSG mice with luciferase-labeled Tera-2 tumor cells directly into the testes (117). 
Tera-2 cells successfully engrafted, as detected by bioluminescence (BLI) (Fig.2.4A) and retained 
expression of CD30 in situ as assessed by IHC (Fig.2.4B). However, tumors engrafted in mouse testes 
rarely metastasized to extragonadal sites. As intraperitoneal or intravenous administration of EC cells in 
NSG mice resulted in poor tumor engraftment (data not shown) and because metastatic TGCTs typically 
arise in midline locations and retroperitoneum (124), we engrafted Tera-2 cells orthotopically under the 
kidney capsule as a clinically relevant model of metastatic EC. When analyzed by IHC, tumors were 
located under the renal capsule, sometimes infiltrating into the subjacent cortex or deeper into the medulla 
(Fig.2.S4D). In this tumor model, luciferase-labeled CD30.CAR-Ts injected intravenously via tail vein 
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(i.v.) consistently localized and accumulated at the tumor site. While CD30.BB-Ts showed increased 
accumulation early after injection, CD30.28-Ts showed better long-term persistence compared to that of 
controls (Ctr.Ts) or CD30.BB-Ts (Fig.2.4C and 2.S4A). T cells were detectable in the blood (Fig.2.S4B) 
and spleen (Fig.2.S4C) in all treatment groups between day 30–45 post T cell infusion. In tumor 
specimens collected between day 30–45 post T cell infusion, we observed infiltrating CD3+ T cells that 
occasionally formed small clusters (Fig.2.S4D). However, no significant differences in CD3+ T cell 
infiltration between Ctr-T and CD30.CAR-T treated groups were observed (Fig.2.4D). 
To test CD30.CAR-T anti-tumor activity, luciferase-labeled EC cells were engrafted in the kidney 
and tumor growth measured by BLI. When tumors in the kidney showed consistent increase in BLI, mice 
received i.v. unlabeled Ctr.Ts or CD30.CAR-Ts. Both CD30.28-Ts and CD30.BB-Ts reduced the tumor 
growth compared to Ctr.Ts (Fig.2.4E and 2.S4E), but CD30.28-Ts provided better survival when using 
tumor BLI of 5 x 107 p/s as a survival cutoff (Fig.2.4F). 
CD30– EC cells are eliminated by CD30.CAR-Ts via antigen-independent, but cell-cell 
contact-dependent mechanisms. While not displaying lytic activity against CD30– tumor cells alone in 
short-term (Fig.2.2A) or long-term (Fig.2.S2A) assays, CD30.CAR-Ts completely eliminated Tera-1 
cells, which contain a mixture of CD30+ and CD30– cells (Fig.2.1A), in 5-day co-culture assays 
(Fig.2.2B). To dissect this phenomenon, we co-cultured CD30.CAR-Ts with CD30– flow-sorted Tera-1 
cells (Fig.2.5A) and found that they were no longer eliminated (Fig.2.5B), with no detectable IFNγ or IL-
2 released in culture supernatants (Fig.2.S5B). In addition, when unselected Tera-1 cells were co-cultured 
with CD30.CAR-Ts at very low E:T ratios, CD30+ Tera-1 cells were preferentially eliminated over the 
CD30– fraction (Fig.2.5C). Similar results were observed with CD30.BB-Ts (Fig.2.S5). We found no 
evidence of CD30 upregulation in CD30– Tera-1 cells when these cells were exposed to soluble factors 
released by CD30.CAR-Ts such as IFNγ and TNFα, or when exposed to co-culture supernatants (data not 
shown). By contrast, we observed that Tera-1 cells were eliminated in a CD30 antigen-independent 
manner by activated CAR-Ts. To conclusively support this observation, we co-cultured Tera-1 cells with 
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CD19.CAR-Ts, which target the CD19 antigen that is not expressed by EC cells, in the presence of 
CD19– (K562/WT) or CD19+ (K562/CD19+) target cells to induce CAR-T activation. As shown in 
Fig.2.5D, CD19.CAR-Ts eliminated Tera-1 cells only in the presence of K562/CD19+ cells. Furthermore, 
the elimination of Tera-1 cells was T cell-tumor cell contact-dependent since the anti-tumor effects were 
abolished when CD19.CAR-Ts and K562/CD19+ cells were separated from Tera-1 cells using a transwell 
(Fig.2.5E). These data suggest that CD30.CAR-Ts, upon activation through the CAR, can eliminate the 
fraction of Tera-1 cells that is CD30– cells in a cell-cell contact dependent, but antigen-independent 
mechanism. 
Fas/FasL pathway mediates the elimination of CD30– EC cells and improves the elimination 
of CD30+ EC cells by CD30.CAR-Ts. Fas-FasL (CD95/CD95L) interactions between tumor cells and 
cytotoxic T lymphocytes contribute to tumor cell death (125). CAR-Ts also upregulate FasL upon 
receptor engagement (126;127), and Tera-1 cells express Fas (Fig.2.6A). Since the CD30– fraction of 
Tera-1 cells also retains Fas expression (Fig.2.6B), we investigated whether CD30.CAR-Ts utilize the 
Fas/FasL pathway to eliminate the CD30– fraction of Tera-1 cells. CD30.28-Ts upregulated FasL upon 
CAR engagement with EC cells after 4 hours in vitro (Fig.2.6C). In contrast, EC cell lines neither 
expressed FasL mRNA nor secreted FasL in culture supernatants (data not shown). When co-cultured 
with CD30.28-Ts, the CD30– fraction of Tera-1 cells showed caspase 3 activity (Fig.2.6D), which is 
primarily triggered by the Fas/FasL pathway (125). By contrast, cell death of the CD30+ fraction was 
primarily caused by granzyme B/perforin-mediated membrane damage as detected by cleaved caspase 7 
(128;129) (Fig.2.6E). When CD95 was knocked down in Tera-1 cells via specific siRNA (115) (Tera-
1/CD95 KO, Fig.2.6F), we found reduced caspase 3 activity among CD30– Tera-1 cells compared to 
wildtype Tera-1 cells when co-cultured with CD30.28-Ts (Fig.2.6G). Similar Fas/FasL-mediated effects 
were observed when the experiments were repeated using CD30.BB-Ts (Fig.2.S6).  
To assess if the pattern of antigen-independent Fas/FasL mediated elimination of tumor cells was 
broadly applicable, we evaluated CD95 on the two other EC tumor cell lines Tera-2 and NCCIT. Notably, 
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Tera-2 cells that express CD95 (Fig.2.6A) were similarly targeted via antigen-independent Fas/FasL 
killing by CD19.CAR-Ts (Fig.2.S7A), but not NCCIT cells (Fig.2.S7B) that lack CD95 expression 
(Fig.2.6A). Interestingly NCCIT cells appeared constitutively more resistant to CD30.CAR-T mediated 
killing (Fig.2.2D and 2.S7C) and showed significantly decreased expression of apoptosis-related genes by 
RNA-Seq (notably p53, Fas, and TRAIL receptor) compared to either Tera-1 or Tera-2, which showed 
greater co-clustering of apoptosis-related gene expression patterns (Fig.2.S7D and Supplemental Table). 
However, when engineered to express CD95 (NCCIT/CD95+, Fig.2.6H), NCCIT cells were more 
efficiently eliminated by CD30.28-Ts (Fig.2.6I). These data suggest that introducing Fas/FasL 
interactions via CD95 overexpression on EC cells is sufficient to improve CD30.CAR-T anti-tumor 
activity. 
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2.4 Discussion 
Investigation of novel drugs for the treatment of ECs and TGCTs in general did not significantly 
progress in the past few decades, and the outcome of patients treated with new drugs remains poor with 
an overall survival rate of 30–40% (106). As previously identified in Hodgkin’s lymphoma (97;98), 
CD30 expression by ECs can be exploited to develop targeted therapies in these malignancies. CD30 is 
found on ECs at diagnosis and its expression is retained in a significant number of patients who 
progressed after multiple chemotherapy regimens (108). Promising results have been reported using 
brentuximab vedotin in relapsed TGCT patients enrolled in clinical studies (110;130) and clinical 
outcome will likely be further improved in combination with other agents.  
Here we propose CD30.CAR-Ts as a valuable approach to enhance the therapeutic index of 
CD30-targeted therapies in ECs. We recently reported that autologous CD30.CAR-Ts were safe in 
patients with relapsed CD30+ lymphomas, with promising anti-tumor activity documented even in the 
absence of a conditioning regimen before infusing CD30.CAR-Ts (98). In our preclinical study using 
CD30+ ECs, we show that CD30.CAR-Ts can selectively target human EC cell lines, localize at the tumor 
site in vivo and control tumor growth. 
The presence of the EC subtype among NS-TGCTs correlates with higher rates of relapse after 
chemotherapy (103), which may be driven, at least in part, by the intrinsic stem cell properties of ECs 
(131). Cancer stem cells, which differentiate into multiple tumor cell types, are indeed often resistant to 
chemotherapy and act as a reservoir of tumor cells that ultimately leads to recurrence (132). Herszfeld et 
al. specifically linked CD30 expression to enhanced tumorigenic features among transformed 
hematopoietic stem cells (87). Because CD30 expression is retained by putative EC stem cells identified 
as SP cells (121), targeting this molecule with CAR-Ts may prove significantly advantageous to 
ultimately overcome the drug resistance of these tumor cells. Therefore, CD30.CAR-Ts may potentially 
reduce the chance of relapse by eliminating the reservoir of stem cell-like ECs, in addition to 
differentiated ECs. 
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Another common cause of tumor escape and relapse after targeted immunotherapy is the 
heterogeneous expression of target antigens within the tumor. For example, some leukemia patients 
showed emergence of CD19– leukemic cells after adoptive transfer of CD19-specific CAR-Ts due to 
selection of alternatively spliced CD19 isoforms (133). Similarly, tumor escape due to antigen loss has 
been observed in patients with glioblastoma treated with EGFRvIII-specific CAR-Ts (134). Bi-specific 
CAR-Ts which target two antigens simultaneously (135;136) can reduce tumor escape, but my also 
increase the risk of toxicities in normal tissues due to on-target off-tumor effects, especially in solid 
tumors, which frequently share antigens with normal tissues. Here we show that the observed Fas-FasL 
interaction between ECs and CD30.CAR-Ts may represent a novel way to overcome tumor escape 
associated with antigen heterogeneity. Specifically, we observed that CD30.CAR-Ts can target CD30– EC 
cells in a contact-dependent manner via Fas/FasL interaction. While eradicating CD30+ EC cells via 
perforin/granzyme B-mediated mechanisms, CD30.CAR-Ts also upregulate FasL and eliminate 
surrounding CD30– tumor cells, if they express the CD95 molecule, via caspase 3 activation. 
The Fas/FasL pathway is highly relevant in tumor immunology (137;138), and Fas agonist mAbs 
have been developed to activate the apoptotic cascade in tumor cells (139). However, this strategy was 
not clinically developed due to the systemic toxicities caused by the nonselective targeting of CD95 
expressing cells in normal tissues, such as hepatocytes (140;141). In this regard, the FasL mechanism 
exploited by CAR-Ts, which is cell-cell contact dependent, is more regulated than systemic Fas targeting 
by mAbs, since upregulation of FasL by CAR-Ts only occurs at the tumor site after antigen-specific 
engagement. Nevertheless, while our data indicate that the Fas/FasL pathway is critical for CD30.CAR-Ts 
to eliminate surrounding antigen-negative tumor cells, tumor cells can downregulate Fas (137;142;143) or 
develop non-functional Fas mutations as in EC (144) to escape immune cell targeting. The EC cell line 
NCCIT is a typical example of Fas– tumor cell line, and we observed that this cell line is indeed more 
resistant to the cytolytic activity of CD30.CAR-Ts. This effect can be reverted, however, by promoting 
expression of functional Fas in these cells. These data thus highlight an innovative approach to exploit the 
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Fas/FasL pathway in adoptive T cell immunotherapy and specifically in CAR-T-based therapies. We have 
previously reported that oncolytic viruses that specifically infect and replicate within tumor cells can be 
armed to attract CAR-Ts at the tumor site and sustain their proliferation by releasing RANTES and IL-15, 
respectively (145). In light of our novel results, we can speculate that oncolytic viruses further engineered 
to cause high expression of functional Fas selectively in tumor cells will be valuable when combined with 
CAR-T therapy to promote both antigen-dependent CAR-mediated and antigen-independent Fas/FasL 
mediated elimination of tumor cells. 
Although effective in targeting CD30+, CD30– EC cells and EC stem-like EC cells in vitro, 
CD30.CAR-Ts did not completely eradicate EC tumors in vivo in our aggressive EC model in which the 
tumor is engrafted within the kidney. CD30.CAR-Ts upon i.v. inoculation localized at the tumor and 
showed some level of expansion within the tumor. However, the observed localization, expansion and 
persistence of CD30.CAR-Ts in our model remained suboptimal to fully eradicate the tumor. Several 
strategies have been proposed to further enhance CAR-T migration, infiltration and persistence within the 
tumor, such as engineering CAR-Ts to express heparanase to degrade tumor extracellular matrix (118) or 
constitutive expression of cytokines (146;147). In addition, combination with other agents may also 
improve the anti-tumor activity of CAR-Ts. For instance, PD-L1 is highly expressed in some EC tumors 
(148). While PD1/PD-L1 blockades as single agents may not be effective in TGCTs due to its low 
mutation rates (149), these inhibitors may prevent the exhaustion of CD30.CAR-Ts that express PD1 
upon activation (150).  
In summary, we found that CD30.CAR-Ts represent a clinically applicable strategy in patients 
with ECs. We have demonstrated that CD30.CAR-Ts are effective against ECs targeting both 
differentiated and stem cell-like EC cells. We also highlighted the relevance of the Fas/FasL pathway in 
CAR-T function and how this pathway can be exploited to counter tumor escape due to the 
downregulation of the targeted antigen by tumor cells, as well as to enhance cytolytic activity of CAR-Ts. 
Finally, since CD30 is expressed in other solid tumors such as neoplasms with chondroid differentiation 
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that still have dismal outcomes (151), CD30.CAR-Ts represent a novel and promising treatment for other 
CD30+ non-lymphomatous malignancies. 
2.5 Authorship Contributions 
LKH, GD and BS designed the experiments. LKH conducted the experiments and analyzed the 
data. YC created the CD30.CAR-T retroviral plasmid constructs and performed validation studies using a 
Hodgkin’s Lymphoma model. CCS and BV performed the RNA-Seq data analysis. SM described and 
performed quantitative analysis of tissue slides in a blinded fashion. LKH, GD and BS wrote the 
manuscript, and all authors edited and approved the manuscript.                 
 
 
27 
 
2.6 Figures 
 
Figure 2.1: CD30 is expressed by EC cell lines and primary ECs. (A) CD30 expression was detected 
on EC tumor cell lines Tera-1, Tera-2 and NCCIT by flow cytometry using the anti-human CD30 mAb 
(Clone Ber-H3). The neuroblastoma cell lines Lan-1/WT and Lan-1/CD30 were used as CD30 negative 
and positive control, respectively. The Hodgkin’s lymphoma cell line HDLM-2 was used as a naturally-
expressing CD30 control tumor cell line. Frequency of positive cells and mean fluorescent intensity 
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(MFI) are indicated. (B) Representative IHC for CD30 expression with nuclear counterstain in human 
tissue microarray (TMA) including normal testes, seminoma (stage I T1N0M0), and ECs (stage I 
T2N0M0) at 10X magnification, scale bar=100μm. IHC was performed using the anti-human CD30 mAb 
(Clone Ber-H2). (C,D) Cumulative analysis of CD30 expression for the TMA shown as H score (C), an 
algorithm calculated based on membrane staining frequency and intensity, or as frequency of positive 
cells (D). For both panels, each data point represents one tissue sample with mean ± SEM for each group 
of tissues/tumors. ***=p<0.001, one-way ANOVA. 
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Figure 2.2: CD30.CAR-Ts exhibit cytotoxic activity against EC cell lines in vitro. (A) 51Cr release 
assay of control T cells (Ctr.T), CD30.28-Ts and CD30.BB-Ts against tumor cell lines indicated (mean ± 
SEM, n = 4 donors). ns=not significant, *=p<0.05, **=p<0.01, ***=p<0.001, repeated measures one-way 
ANOVA comparing individual effector:target (E:T) ratios. (B-D) Ctr.T or CD30.CAR-Ts were co-
cultured with the EC cell line Tera-1 (B), Tera-2 (C) or NCCIT (D). By day 5 remaining EC cells 
(CD30+) and T cells (CD3+) were collected and analyzed by flow cytometry. Representative flow plots at 
1:1 (B,C) or 5:1 (D) E:T ratios (left panels) and cumulative data for remaining frequency of CD30+ cells 
for all E:T ratios tested (right panels) are shown (mean ± SEM, n = 4–5 donors). *=p<0.05, **=p<0.01, 
***=p<0.001, two-sided, paired Student’s T test. 
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Figure 2.3: EC-derived SP cells are targeted by CD30.CAR-Ts. (A) Flow cytometry plots of Hoechst 
33342-stained tumor cell lines in which percentages of SP and non-SP cells are shown for each tumor cell 
line (upper panels). Histograms of CD30 expression and MFI on pre-gated SP and non-SP cells are shown 
(lower panels). Raji cells were used as CD30– control cells. (B) Tera-1 SP and non-SP cells were 
identified by dye cycle violet staining and FACS-sorted. RNA was extracted, retro-transcribed and 
amplified by RT-qPCR to measure the expression of the stem cell markers ABCG2 and SOX2. Each bar 
represents the mean ± SEM of three biological replicates. (C) SP cells were sorted from the Tera-1 cell 
31 
 
line and cultured in vitro for 6 weeks. SP-sorted cells regenerated both SP and non-SP cells. (D) Ctr.T or 
CD30.CAR-Ts were co-cultured with SP-sorted Tera-1 cells at a 1:1 E:T ratio for 5 days, followed by 
flow cytometry analysis to detect remaining CD3+ T cells and CD30+ tumor cells. Flow cytometry plots 
of one representative donor are shown (n = 2). 
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Figure 2.4: CD30.CAR-Ts localize to EC tumors and exhibit anti-tumor activity in vivo. (A) 
Representative in vivo IVIS imaging of NSG mice inoculated with 2 × 106 Tera-2 cells labeled with 
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eGFP-FFLuc into the left testis. (B) Representative hematoxylin/eosin (H&E) and human CD30 IHC 
staining of EC tumors growing in the testis are shown at 4X magnification, scale bar=250 μm. (C) NSG 
mice were inoculated with Tera-2 cells under the left kidney capsule and, 21 days later, infused i.v. with 1 
× 107 eGFP-FFLuc-labeled CD30.CAR-Ts or CD19.CAR-Ts (Ctr.T). Representative IVIS images 
indicating CAR-T localization and expansion (left panel) and cumulative BLI (right panel) are shown 
(mean ± SEM, n=3–4 per group, 2 independent experiments). **=p<0.001, one-way ANOVA at day 12. 
(D) T cell-treated mice were sacrificed at day 30–45 post tumor inoculation and tumors were stained with 
anti-human CD3 mAb to detect tumor-infiltrating T lymphocytes. CD3+ T cells were counted at 400x 
magnification with the tumor covering at least 80% of the field of view in a blinded fashion. Cumulative 
quantification of CD3+ T cell counts are shown (mean ± SEM, n=1–3 per group, 4 independent 
experiments). ns=not significant, one-way ANOVA. (E) NSG mice were inoculated with Tera-2 cells 
labeled with eGFP-FFLuc under the left kidney capsule and received 1 × 107 CD30.CAR-Ts or 
CD19.CAR-Ts (Ctr.T) i.v. by day 15. Representative IVIS images indicating tumor growth (left panel) 
and cumulative BLI (right panel) are illustrated (mean ± SEM, n = 4–5 per group, 2 independent 
experiments). **=p<0.001, one-way ANOVA at day 42. (F) Cumulative Kaplan-Meier survival curve of 
BLI <5 x 107 p/s for 2 independent experiments. *=p<0.05 by log-rank (Mantel-Cox) test. 
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Figure 2.5: CD30.CAR-Ts eliminate Tera-1 CD30– cells in a cell contact-dependent but antigen-
independent manner. (A) Tera-1 cells were FACS-sorted to obtain CD30+ and CD30– cells. Histogram 
shows CD30 expression on sorted cells. (B) Sorted Tera-1 CD30+ and CD30– cells were labeled with 
CFSE and co-cultured with either Ctr.Ts or CD30.28-Ts for 5 days. Cells were then collected and 
evaluated by flow cytometry to quantify T cells (CD3+) and tumor cells (CFSE+). Representative flow 
plots (top panels) and cumulative data (bottom panels) summarizing CFSE+ tumor cell frequency (mean ± 
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SEM, n = 4 donors) are shown. ns = not significant, **=p<0.01, two-sided, paired Student’s T test. (C) 
Tera-1 cells were labeled with CFSE and co-cultured for 5 days with CD30.28-Ts at decreasing E:T ratios 
ranging from 1:1 to 1:15. Representative plots (left columns) and CD30 histograms (right columns) of 
CFSE+ Tera-1 cells with cumulative data (right graph) for remaining tumor cells calculated with flow 
cytometry-based counting beads are shown (mean ± SEM, n = 5 donors). *=p<0.05, **=p<0.01, two-
sided, paired Student’s T test. (D) Tera-1 cells were co-cultured with CD19.CAR-Ts in the presence of 
either K562/WT or K562/CD19+ cells at 1:1:1 ratio for 5 days. Cells were then collected and evaluated by 
flow cytometry to quantify T cells (CD3+) and tumor cells (CD30+). Shown are representative flow 
cytometry plots of CD3+ T cells and CD30+ EC cells pre-gated to exclude CD33+ K562 cells (left panels) 
and cumulative data summarizing tumor cell numbers (right panels). Dashed line represents the initial 
Tera-1 cell number (mean ± SEM, n=5 donors). *=p<0.05, two-sided, paired Student’s T test. (E) Tera-1 
cells were plated in the lower chamber of a 0.4μm transwell-plate 24 hours prior to plating CD19.CAR-Ts 
and either K562/WT or K562/CD19+ cells in the upper chamber at 1:1:1 ratio for 5 days. Tera-1 cells in 
the lower chamber were then collected and counted by flow cytometry. Cumulative data are shown, 
dashed line represents the initial cell number (mean ± SEM, n = 7 donors). ns=not significant, *=p<0.05, 
two-sided, paired Student’s T test. 
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Figure 2.6: Functional Fas-FasL interaction is critical for the elimination of CD30– EC cells and 
enhances anti-tumor activity of CD30.CAR-Ts. (A) Flow cytometry histograms showing CD95 
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expression and MFI in EC cell lines. T cells stimulated with anti-CD3/CD28 mAbs were used as positive 
control for CD95 expression. (B) CD95 expression on pre-gated CD30+ or CD30– Tera-1 cells. (C) RT-
qPCR cumulative data for FasL mRNA expression among Ctr.T or CD30.28-Ts cultured alone or with 
EC cells at a 5:1 E:T ratio for 4 hours at 37°C (mean ± SEM, n = 6 donors). FasL mRNA expression was 
normalized to β-actin mRNA. ns = not significant, ***=p<0.0001, two-sided paired Student’s T test. (D-
E) Active caspase 3 and cleaved caspase 7 were assessed by flow cytometry in Tera-1 cells co-cultured 
with Ctr.T or CD30.28-Ts at 1:2 or 1:5 E:T ratio for 18 hours, respectively. Representative flow plots (left 
panels) and cumulative data (right panels) of active caspase 3 frequency (D) or cleaved caspase 7 MFI (E) 
among Tera-1 CD30– and CD30+ cells, respectively are shown (mean ± SEM, n = 5 donors). *=p<0.05, 
**=p<0.01, two-sided, paired Student’s T test. (F) CD95 expression on pre-gated CD30– cells for Tera-
1/WT or Tera-1 cells transduced with CD95 shRNA and FACS-sorted based on CD95– expression (Tera-
1/CD95 KO) is shown. CD95 frequency and MFI for Tera-1/CD95 KO cells are indicated. (G) Tera-
1/WT or Tera-1/CD95 KO cells were co-cultured with Ctr.Ts or CD30.28-Ts at 1:5 E:T ratio for 18 
hours. Representative flow plots (left panels) and cumulative data (right panels) for active caspase 3 
among Tera-1 CD30– cells are shown (mean ± SEM, n = 4 donors). ns = not significant, ***=p<0.001, 
two-sided, paired Student’s T test. (H) CD95 expression on NCCIT/WT cells and NCCIT cells 
transduced to express CD95 (NCCIT/CD95+). CD95 frequency and MFI for NCCIT/CD95+cells are 
indicated. (I) NCCIT/WT or NCCIT/CD95+ cells were co-cultured with Ctr.Ts or CD30.28-Ts at 1:2 E:T 
ratio for 5 days. Representative flow plots (left panels) and cumulative data (right panels) showing 
remaining tumor cells are illustrated (mean ± SEM, n = 4 donors). ns = not significant, *=p<0.05, two-
sided, paired Student’s T test. 
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Figure 2.S1: CD30.CAR-T characteristics. (A) Schematic of CD30.CARs encoding either the CD28 
(CD30.28-T) or the 4-1BB (CD30.BB-T) endodomains. The anti-CD30 scFv domain (aCD30 scFv) was 
cloned in frame with CD8α hinge and transmembrane domain (TM) and either CD28 or 4-1BB 
endodomains with CD3z. (B) CAR transduction efficiency was detected by flow cytometry using an anti-
mouse Alexa Fluor 647-conjugated F(ab’)2 antibody. Representative histograms (top panels) and 
cumulative data (bottom panels) are shown (mean ± SEM, n=7 donors). ***=p<0.001, repeated-measures 
ANOVA. (C) Cumulative data for CAR-T expansion in vitro at day 2/3 and day 7 post transduction 
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(mean ± SEM, n=5 donors). *=p<0.05, repeated-measures ANOVA. (D) CAR-T immunophenotype by 
day 7 post-transduction. Representative plots pre-gated on CD3+ T cells (top panels) and cumulative data 
for CCR7+CD45RA+ stem cell-like memory T cells (top graph) (23) and CD45RA–CD45RO+ central and 
effector memory T cells (bottom graph) are shown (mean ± SEM, n=5 donors). ns=not significant, two-
sided, paired Student’s T test. 
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Figure 2.S2: Co-culture of CD30.CAR-Ts and tumor cells. (A) Representative flow plots (left panels) 
and cumulative data (right panels) of 5-day co-culture assays of CD30.CAR-Ts with Lan-1/WT (CD30–) 
or Lan-1/CD30 (CD30+) tumor cells labeled with anti-GD2 mAb (mean ± SEM, n=4 donors). ns=not 
significant, **=p<0.01, ***=p<0.001, two-sided, paired Student’s T test. (B-D) Representative flow plots 
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of CD30.CAR-T co-cultures with Tera-1 (B) or Tera-2 (C) cells at the 1:2 and 1:5 E:T ratios, and of 
CD30.CAR-T co-culture with NCCIT cells (D) at 1:1 and 2.5:1 E:T ratios. 
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Figure 2.S3: CD30.CAR-Ts proliferate and secrete pro-inflammatory cytokines in response to EC 
cell lines. (A) Representative histograms (left panels) and cumulative data (right panels) of CFSE dilution 
of CFSE-labeled CD3+ Ctr.Ts, CD30.28-Ts and CD30.4-1BB-Ts after 5 days alone or in co-culture with 
tumor cells (mean ± SEM of CFSE MFI, n=5 donors). ns=not significant, *=p<0.05, **=p<0.01, 
***=p<0.001, two-sided, paired Student’s T test. (B-C) Cumulative quantification by ELISA of IFNγ (B) 
and IL-2 (C) released in co-culture supernatant after 24 hours by Ctr.Ts, CD30.28-Ts and CD30.4-1BB-
Ts with either CD30+ or CD30- tumor cells at 1:1 E:T ratio (mean ± SEM, n=5 donors). ns= not 
significant, *=p<0.05, **=p<0.01, ***=p<0.001, two-sided, paired Student’s T test. 
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Figure 2.S4: CD30.CAR-T expansion and anti-tumor activity in vivo. (A) NSG mice were inoculated 
with Tera-2 cells under the left kidney capsule and, 21 days later, infused i.v. with 1 × 107 eGFP-FFLuc-
labeled CD30.CAR-Ts or CD19.CAR-Ts (Ctr.T). BLI from individual mice are shown (n=3-4 per group, 
2 independent experiments). **=p<0.001, one-way ANOVA at day 12. (B-C) T cell-treated mice were 
sacrificed at day 30-45 post tumor inoculation, and blood samples (B) and spleens (C) were collected to 
detect human CD45+CD3+ T cells. Blood samples were normalized to 100μL total volume. Cumulative 
quantification of %CD45+CD3+ T cells are shown (mean ± SEM; n=1-5 per group, 4 independent 
experiments). (D) Tumors were harvested at day 30-45 post tumor inoculation and stained for 
hematoxylin/eosin (H&E) or anti-human CD3 mAb to detect tumor-infiltrating T lymphocytes. Positive 
samples displayed moderate to strong, diffuse cytoplasmic labeling for CD3, at 4X magnification, scale 
bar=200μm. Arrow=tumor, *=CD3 T cell clusters. (E) NSG mice were inoculated with Tera-2 cells 
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labeled with eGFP-FFLuc under the left kidney capsule and received 1 × 107 CD30.CAR-Ts or 
CD19.CAR-Ts (Ctr.T) i.v. by day 15. BLI from individual mice are illustrated (n=4-5 per group, 2 
independent experiments). **=p<0.001, one-way ANOVA at day 42. 
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Figure 2.S5: Tera-1 CD30– cells are eliminated by CAR-Ts in a cell contact-dependent but antigen-
independent manner. (A) Sorted Tera-1 CD30+ and CD30– cells were labeled with CFSE and co-
cultured with either Ctr.Ts or CD30.BB-Ts for 5 days, and then analyzed by flow cytometry. Shown are 
representative flow plots (top panels) and cumulative data (bottom panels) summarizing tumor cell 
frequency (mean ± SEM, n=4 donors). *=p<0.05, **=p<0.01, two-sided, paired Student’s T test. (B) 
Cumulative data for IFNγ (top panels) and IL-2 (bottom panels) release by Ctr.Ts, CD30.28-Ts and 
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CD30.4-1BB-Ts in the supernatant of co-culture with Tera-1 CD30+ or CD30– cells at 1:1 E:T ratio are 
shown (mean ± SEM, n=4 donors). ns= not significant, *=p<0.05, **=p<0.01, ***=p<0.001, two-sided 
paired Student’s T test. (C) Representative plots (left columns) and CD30 histograms (right columns) of 
CFSE+ Tera-1 cells co-cultured for 5 days with CD30.BB-Ts at decreasing E:T ratios and cumulative data 
(right graph) for remaining tumor cells calculated with flow cytometry-based counting beads are shown 
(mean ± SEM, n=5 donors). ns=not significant, *=p<0.05, **=p<0.01, two-sided, paired Student’s T test. 
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Figure 2.S6: Functional Fas-FasL interaction is critical for the elimination of CD30– EC cells by 
CD30.CAR-Ts. (A) FasL mRNA expression measured by RT-qPCR of CD30.BB-Ts cultured alone or 
with EC cells at a 5:1 E:T ratio for 4 hours at 37°C. Expression is normalized to housekeeping gene β-
actin. n=6 independent experiments; **=p<0.001 by two-sided, paired Student’s T test. (B-C) 
Representative flow plots (left panels) of active caspase 3 (B) or cleaved caspase 7 (C) staining pre-gated 
on Tera-1 CD30–  or CD30+ cells after co-culture with Ctr.Ts or CD30.BBTs for 18 hours at 37°C and 
cumulative data (right panels) are shown (mean ± SEM, n=5 donors). *=p<0.05, **=p<0.001, two-sided, 
paired Student’s T test. (D) Tera-1/WT or Tera-1/CD95 KO cells were co-cultured with Ctr.Ts or 
CD30.BB-Ts at 1:5 E:T ratio for 18 hours. Representative flow plots (left panels) and cumulative data 
(right panels) for active caspase 3 among Tera-1 CD30– cells are shown (mean ± SEM, n=4 donors). 
**=p<0.001, two-sided, paired Student’s T test.  
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Figure 2.S7: Tera-2 cells are susceptible to antigen-independent killing by CD30.CAR-Ts, while 
NCCIT cells are resistant to CD30.CAR-T targeting. (A-B) Tera-2 (A) and NCCIT (B) cells were co-
cultured with CD19.CAR-Ts in the presence of either K562/WT or K562/CD19+ cells at 1:1:1 ratio for 5 
days, and then analyzed by flow cytometry to detect T cells (CD3+) and CD30+ EC cells after excluding 
CD33+ K562 cells. Cell numbers were calculated using flow cytometry-based counting beads. 
Representative flow plots (left panels) and cumulative data (right panels) summarizing tumor cell 
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numbers with the dashed lines indicating initial tumor cell numbers are shown (mean ± SEM, n=5 
donors). ns=not significant, *=p<0.05, two-sided, paired Student’s T test. (C) 51Cr release assay of control 
T cells (Ctr.T), CD30.28-Ts and CD30.BB-Ts against NCCIT cells (mean ± SEM, n=4 donors). ns=not 
significant, repeated measures one-way ANOVA comparing individual effector:target (E:T) ratios. (D) 
Heatmap showing expression of differentially expressed genes between NCCIT, Tera-1, and Tera-2 cells 
within the MSigDB KEGG Apoptosis and Biocarta c2 p53 pathways, scaled by samples. Dendrogram 
represents hierarchical clustering based upon complete linkage of the Euclidean distances of gene 
expression.   
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2.7 Tables 
Name Fold_Change pValue FDR FDR_pValue Pathway 
TNFRSF10C|8794 66.04886 3.00E-27 1.75E-25 1.21E-25 Apoptosis 
FAS|355 41.49672 3.68E-45 5.67E-43 5.93E-43 Apoptosis 
IRAK1|3654 37.22048 2.12E-23 9.85E-22 6.81E-22 Apoptosis 
BAX|581 13.61859 3.21E-13 6.53E-12 4.70E-12 Apoptosis 
IL1A|3552 10.06591 1.74E-17 5.39E-16 4.01E-16 Apoptosis 
IRAK3|11213 6.468845 4.77E-09 5.90E-08 3.65E-08 Apoptosis 
TP53|7157 5.769441 2.28E-09 2.96E-08 2.04E-08 Apoptosis 
IL1RAP|3556 4.534274 4.38E-05 0.000258 0.000185669 Apoptosis 
AKT3|10000 3.833167 4.69E-12 8.41E-11 6.29E-11 Apoptosis 
PIK3CB|5291 2.863943 5.62E-06 4.00E-05 2.92E-05 Apoptosis 
PPP3CC|5533 2.863359 3.18E-05 0.000193 0.000143559 Apoptosis 
CASP8|841 2.800288 4.70E-06 3.40E-05 2.52E-05 Apoptosis 
TNFRSF1A|7132 2.602997 3.28E-05 0.000198 0.000143559 Apoptosis 
BCL2L1|598 2.529618 0.013219 0.037486 0.03224637 Apoptosis 
CASP7|840 2.484147 0.001036 0.004231 0.003474941 Apoptosis 
CYCS|54205 2.302319 0.006106 0.019478 0.016115773 Apoptosis 
TNFRSF10B|8795 2.21098 0.00061 0.002669 0.00213417 Apoptosis 
PIK3CD|5293 2.043929 0.01553 0.042942 0.036768477 Apoptosis 
NFKBIA|4792 1.907605 0.001278 0.005095 0.004065303 Apoptosis 
TNFRSF10A|8797 1.739238 0.030244 0.074595 0.064069802 Apoptosis 
CAPN1|823 1.682036 0.26243 0.403895 0.370625045 Apoptosis 
RELA|5970 1.671595 0.152998 0.270074 0.256590082 Apoptosis 
PRKAR2B|5577 1.446705 0.167047 0.28839 0.269084695 Apoptosis 
NFKB1|4790 1.377542 0.174565 0.298168 0.270240809 Apoptosis 
PRKAR1A|5573 1.308662 0.180944 0.306422 0.27744725 Apoptosis 
PRKX|5613 1.230738 0.408733 0.555538 0.530694185 Apoptosis 
CASP3|836 1.229529 0.492671 0.632681 0.619687895 Apoptosis 
IL1R1|3554 1.181133 0.629068 0.745153 0.753036565 Apoptosis 
TNFRSF10D|8793 1.143618 0.654343 0.763955 0.767019413 Apoptosis 
PPP3CB|5532 1.085238 0.725897 0.817087 0.828861566 Apoptosis 
AKT2|208 1.071054 0.795687 0.866276 0.883486841 Apoptosis 
IKBKB|3551 1.023179 0.925571 0.951552 0.951425781 Apoptosis 
CHUK|1147 1.021913 0.92225 0.949446 0.951425781 Apoptosis 
CASP6|839 1.01198 0.959633 0.974305 0.96563033 Apoptosis 
ENDOD1|23052 1.006705 0.978079 0.985916 0.978078592 Apoptosis 
PRKAR1B|5575 0.964554 0.94092 0.961799 0.95878506 Apoptosis 
PIK3R1|5295 0.949455 0.815978 0.879873 0.899811369 Apoptosis 
CFLAR|8837 0.874773 0.631428 0.746934 0.753036565 Apoptosis 
DFFB|1677 0.81684 0.327852 0.47439 0.439867876 Apoptosis 
TNFSF10|8743 0.775089 0.657445 0.766141 0.767019413 Apoptosis 
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XIAP|331 0.770535 0.276607 0.41901 0.38724984 Apoptosis 
BIRC2|329 0.766289 0.208297 0.340916 0.307668139 Apoptosis 
EXOG|9941 0.724237 0.131974 0.24121 0.226040525 Apoptosis 
PRKACB|5567 0.710461 0.086467 0.173997 0.165727821 Apoptosis 
PPP3CA|5530 0.709012 0.123004 0.228765 0.215256376 Apoptosis 
PIK3R5|23533 0.707977 0.484233 0.624358 0.613869995 Apoptosis 
BID|637 0.670072 0.129262 0.23739 0.223776637 Apoptosis 
APAF1|317 0.658307 0.192457 0.321262 0.292317493 Apoptosis 
AKT1|207 0.654074 0.345873 0.493318 0.460211132 Apoptosis 
PRKACA|5566 0.640399 0.101728 0.196749 0.190444849 Apoptosis 
IRAK4|51135 0.633398 0.034364 0.082561 0.070032373 Apoptosis 
PPP3R1|5534 0.621044 0.021057 0.055439 0.048373518 Apoptosis 
ATM|472 0.581319 0.003016 0.010653 0.008841803 Apoptosis 
CAPN2|824 0.530359 0.168805 0.290604 0.269084695 Apoptosis 
CASP10|843 0.526998 0.010096 0.029869 0.025007758 Apoptosis 
AIFM1|9131 0.475969 0.004981 0.016386 0.013593319 Apoptosis 
BIRC3|330 0.416065 0.021559 0.056554 0.048373518 Apoptosis 
RIPK1|8737 0.398919 0.000319 0.001513 0.001167646 Apoptosis 
BCL2|596 0.364738 0.001288 0.005128 0.004065303 Apoptosis 
CHP1|11261 0.347499 1.14E-09 1.56E-08 1.15E-08 Apoptosis 
PIK3R3|8503 0.336943 0.006932 0.021745 0.017999576 Apoptosis 
PIK3CA|5290 0.323849 2.39E-07 2.21E-06 1.48E-06 Apoptosis 
PIK3R2|5296 0.306998 0.001256 0.005016 0.004065303 Apoptosis 
CASP9|842 0.286904 4.46E-06 3.25E-05 2.48E-05 Apoptosis 
DFFA|1676 0.247858 1.84E-11 3.10E-10 2.28E-10 Apoptosis 
IRAK2|3656 0.146757 3.30E-05 0.000199 0.000143559 Apoptosis 
MYD88|4615 0.133165 1.97E-10 2.96E-09 2.11E-09 Apoptosis 
CDKN1A|1026 8.847523 1.43E-08 1.66E-07 9.59E-08 p53 
CCND1|595 7.818912 1.51E-13 3.19E-12 2.43E-12 p53 
MDM2|4193 3.123406 2.75E-09 3.52E-08 2.22E-08 p53 
GADD45A|1647 2.848898 0.000169 0.000859 0.000648183 p53 
CCNE1|898 1.060314 0.782151 0.85696 0.877994922 p53 
RB1|5925 0.957767 0.838439 0.8948 0.9182901 p53 
CDK4|1019 0.627865 0.243399 0.382387 0.347747843 p53 
PCNA|5111 0.563811 0.029333 0.072814 0.062967477 p53 
CDK2|1017 0.484808 0.003511 0.012149 0.009918345 p53 
E2F1|1869 0.427421 0.07504 0.155499 0.145558697 p53 
Table 2.1: List of differentially expressed apoptosis and p53-related genes between NCCIT and 
Tera-1 cells. 
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Name Fold_Change pValue FDR FDR_pValue Pathway 
TNFRSF10C|8794 79.26094277 1.03E-32 4.89E-31 8.20E-31 Apoptosis 
FAS|355 49.14248522 3.28E-57 4.13E-55 5.25E-55 Apoptosis 
IRAK1|3654 18.37371162 4.28E-16 7.32E-15 5.27E-15 Apoptosis 
ENDOD1|23052 7.985109511 2.83E-24 8.26E-23 6.47E-23 Apoptosis 
IRAK3|11213 6.661140836 8.56E-11 8.77E-10 6.23E-10 Apoptosis 
IL1RAP|3556 4.78794376 3.87E-07 2.46E-06 1.72E-06 Apoptosis 
AKT3|10000 4.735314364 2.67E-16 4.68E-15 3.57E-15 Apoptosis 
TP53|7157 4.708863682 1.28E-10 1.28E-09 8.52E-10 Apoptosis 
CAPN2|824 4.632079192 1.16E-17 2.26E-16 2.06E-16 Apoptosis 
PPP3CC|5533 4.484936372 8.25E-17 1.50E-15 1.32E-15 Apoptosis 
IL1R1|3554 4.0038805 6.53E-08 4.68E-07 3.26E-07 Apoptosis 
TNFRSF10D|8793 3.910728218 1.33E-11 1.50E-10 1.18E-10 Apoptosis 
IL1A|3552 3.371677521 4.68E-05 0.000207626 0.000159389 Apoptosis 
BAX|581 3.239081791 0.004621537 0.012995841 0.010874204 Apoptosis 
BCL2|596 3.170192119 3.18E-08 2.38E-07 1.75E-07 Apoptosis 
PIK3CB|5291 2.995854416 1.89E-07 1.26E-06 8.88E-07 Apoptosis 
NFKBIA|4792 2.962036551 1.03E-10 1.04E-09 7.14E-10 Apoptosis 
PRKX|5613 2.858434188 5.70E-07 3.54E-06 2.47E-06 Apoptosis 
BID|637 2.667998681 2.03E-10 1.98E-09 1.30E-09 Apoptosis 
CASP7|840 2.494259887 1.03E-06 6.16E-06 4.36E-06 Apoptosis 
APAF1|317 2.377093942 0.000573774 0.002022795 0.001639353 Apoptosis 
TNFRSF10A|8797 2.361111555 1.39E-05 6.74E-05 5.05E-05 Apoptosis 
PRKAR2B|5577 2.224876745 0.00040566 0.00148278 0.001201955 Apoptosis 
TNFRSF10B|8795 2.101415936 4.67E-05 0.000207093 0.000159389 Apoptosis 
NFKB1|4790 1.959142734 0.000455298 0.001640874 0.001324502 Apoptosis 
CAPN1|823 1.737886255 0.160489296 0.261007713 0.239983993 Apoptosis 
MYD88|4615 1.714524906 0.067065316 0.12837042 0.11295211 Apoptosis 
TNFRSF1A|7132 1.673030501 0.008968732 0.023139645 0.019391852 Apoptosis 
BIRC2|329 1.581622732 0.022653717 0.051422627 0.045307435 Apoptosis 
CYCS|54205 1.575978476 0.102329084 0.181548919 0.163726534 Apoptosis 
ATM|472 1.482179343 0.00854319 0.022181487 0.018724801 Apoptosis 
PRKAR1B|5575 1.392864048 0.429548655 0.557031724 0.512893916 Apoptosis 
IKBKB|3551 1.290258908 0.146665347 0.243419775 0.223490053 Apoptosis 
PPP3CA|5530 1.285699308 0.206619053 0.318571134 0.287469986 Apoptosis 
CASP6|839 1.262992281 0.201863979 0.312636352 0.283317865 Apoptosis 
CFLAR|8837 1.131022895 0.452614601 0.578809576 0.530074239 Apoptosis 
RELA|5970 1.111006079 0.777321358 0.847211102 0.827247746 Apoptosis 
EXOG|9941 1.103317481 0.641557327 0.739821742 0.69829369 Apoptosis 
BIRC3|330 1.042290371 0.908751185 0.939805503 0.932052497 Apoptosis 
BCL2L1|598 0.945207316 0.836476146 0.890501537 0.874746297 Apoptosis 
CASP3|836 0.898415078 0.62654425 0.728193285 0.686623836 Apoptosis 
AKT2|208 0.879699656 0.592000376 0.700290937 0.654049791 Apoptosis 
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PRKACA|5566 0.871280349 0.592732623 0.700628567 0.654049791 Apoptosis 
CASP8|841 0.858989207 0.406247061 0.53514454 0.501077521 Apoptosis 
PRKACB|5567 0.836574947 0.324255818 0.452074501 0.421796186 Apoptosis 
PRKAR1A|5573 0.80816873 0.247267191 0.366744683 0.339931928 Apoptosis 
CHUK|1147 0.787157479 0.164941721 0.266674437 0.244358105 Apoptosis 
PPP3CB|5532 0.784398382 0.257719604 0.378223507 0.346513754 Apoptosis 
PIK3CD|5293 0.781382066 0.456540662 0.582409349 0.530074239 Apoptosis 
PIK3R2|5296 0.778369745 0.413874247 0.542293105 0.501077521 Apoptosis 
AKT1|207 0.772623031 0.512768653 0.631871396 0.581865138 Apoptosis 
RIPK1|8737 0.759618272 0.260286316 0.381221849 0.347048421 Apoptosis 
PIK3R3|8503 0.741552067 0.157724857 0.257426211 0.238075256 Apoptosis 
PPP3R1|5534 0.674137699 0.044818057 0.091308429 0.079315613 Apoptosis 
TNFSF10|8743 0.595871863 0.416520689 0.544577064 0.501077521 Apoptosis 
PIK3R1|5295 0.588467302 0.011804416 0.029296413 0.024851401 Apoptosis 
IRAK2|3656 0.549876835 0.101224801 0.180052911 0.163595638 Apoptosis 
IRAK4|51135 0.544756549 0.001662357 0.005256548 0.004432951 Apoptosis 
DFFA|1676 0.506572856 0.000402698 0.001473188 0.001201955 Apoptosis 
XIAP|331 0.4424645 0.0006659 0.002316421 0.001869194 Apoptosis 
CHP1|11261 0.409030306 2.26E-09 1.97E-08 1.39E-08 Apoptosis 
AIFM1|9131 0.323699451 2.23E-06 1.24E-05 8.71E-06 Apoptosis 
PIK3CA|5290 0.31678786 6.53E-08 4.68E-07 3.26E-07 Apoptosis 
DFFB|1677 0.309244044 1.13E-06 6.69E-06 4.65E-06 Apoptosis 
CASP10|843 0.18763365 5.21E-11 5.48E-10 4.17E-10 Apoptosis 
CASP9|842 0.17407903 6.57E-11 6.85E-10 5.00E-10 Apoptosis 
PIK3R5|23533 0.149417544 0.000101385 0.000422166 0.000337952 Apoptosis 
CDKN1A|1026 11.77883444 3.35E-13 4.40E-12 3.83E-12 p53 
CCND1|595 7.939426569 2.68E-16 4.70E-15 3.57E-15 p53 
MDM2|4193 3.044055534 4.40E-09 3.69E-08 2.52E-08 p53 
GADD45A|1647 1.834063727 0.002200594 0.006773922 0.00577205 p53 
PCNA|5111 1.255117695 0.114926298 0.199813481 0.182061462 p53 
RB1|5925 1.182573312 0.41089585 0.539300803 0.501077521 p53 
CDK2|1017 1.143256088 0.372636685 0.501122645 0.471782586 p53 
CCNE1|898 0.883146498 0.388482809 0.517008684 0.485603511 p53 
CDK4|1019 0.677339083 0.338303354 0.467656132 0.436520457 p53 
E2F1|1869 0.346079916 0.013166234 0.032194502 0.027358409 p53 
Table 2.2: List of differentially expressed apoptosis and p53-related genes between NCCIT and 
Tera-2 cells. 
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Name Fold_Change pValue FDR FDR_pValue Pathway 
MYD88|4615 12.46815897 9.72E-16 3.49E-14 2.59E-14 Apoptosis 
BCL2|596 8.516785329 3.11E-16 1.17E-14 9.97E-15 Apoptosis 
ENDOD1|23052 7.739959562 2.88E-23 1.82E-21 1.53E-21 Apoptosis 
CAPN2|824 5.977170799 0.003289396 0.011130576 0.012531031 Apoptosis 
BID|637 3.851649622 7.23E-08 8.47E-07 9.64E-07 Apoptosis 
APAF1|317 3.542182649 2.97E-06 2.44E-05 2.64E-05 Apoptosis 
IRAK2|3656 3.462398782 0.027041372 0.064429955 0.069784186 Apoptosis 
TNFRSF10D|8793 3.258378276 6.01E-05 0.000351323 0.000356425 Apoptosis 
IL1R1|3554 3.256809204 8.18E-05 0.000462777 0.000451047 Apoptosis 
PIK3R2|5296 2.528139083 0.005068455 0.015990515 0.018430746 Apoptosis 
ATM|472 2.49856432 2.24E-06 1.88E-05 2.11E-05 Apoptosis 
BIRC3|330 2.488279962 0.00791459 0.023239096 0.026381966 Apoptosis 
PRKX|5613 2.255896724 0.001556888 0.005913995 0.00673249 Apoptosis 
PIK3R3|8503 2.214207744 0.036231183 0.082173687 0.085249842 Apoptosis 
BIRC2|329 2.036362364 5.02E-05 0.000299121 0.00032103 Apoptosis 
DFFA|1676 2.00954999 0.002842337 0.00986931 0.011369348 Apoptosis 
RIPK1|8737 1.876810569 0.011261469 0.031098676 0.034650673 Apoptosis 
PPP3CA|5530 1.786965985 0.003820001 0.012620842 0.014213958 Apoptosis 
NFKBIA|4792 1.518498686 0.033784393 0.077597968 0.080679147 Apoptosis 
PPP3CC|5533 1.507991004 0.080990826 0.156451628 0.164032054 Apoptosis 
PRKAR2B|5577 1.507799462 0.058185199 0.119775731 0.124128424 Apoptosis 
EXOG|9941 1.496709406 0.094323525 0.176622497 0.177550165 Apoptosis 
PRKAR1B|5575 1.405070189 0.437659316 0.569711399 0.593436361 Apoptosis 
NFKB1|4790 1.387362294 0.180753251 0.29437152 0.307665109 Apoptosis 
PRKACA|5566 1.340983855 0.251300117 0.379575176 0.402080187 Apoptosis 
TNFRSF10A|8797 1.323315195 0.254649058 0.383166013 0.403404449 Apoptosis 
CFLAR|8837 1.26852714 0.376265851 0.511567466 0.552316846 Apoptosis 
IKBKB|3551 1.24003076 0.373474464 0.508835497 0.552316846 Apoptosis 
CASP6|839 1.227976307 0.364928833 0.500282716 0.545687974 Apoptosis 
AKT3|10000 1.20897357 0.394195141 0.529308251 0.564164017 Apoptosis 
AKT1|207 1.168980204 0.764759514 0.840944682 0.874010873 Apoptosis 
CHP1|11261 1.164235554 0.384849686 0.519871784 0.559781362 Apoptosis 
PRKACB|5567 1.161607122 0.445690474 0.576676857 0.594253966 Apoptosis 
FAS|355 1.128421539 0.552646459 0.671096484 0.669874496 Apoptosis 
TNFRSF10C|8794 1.089868879 0.715801296 0.803193488 0.845447955 Apoptosis 
PPP3R1|5534 1.071665477 0.734737155 0.817673109 0.84574061 Apoptosis 
PIK3CB|5291 1.023586178 0.916722043 0.945861136 0.964970571 Apoptosis 
IL1RAP|3556 1.00290616 0.991930184 0.994451846 0.996976712 Apoptosis 
CAPN1|823 0.99840346 0.996976712 0.997714697 0.996976712 Apoptosis 
IRAK3|11213 0.988597882 0.97100733 0.981414212 0.995904954 Apoptosis 
CASP7|840 0.973477737 0.914498768 0.944321746 0.964970571 Apoptosis 
PIK3CA|5290 0.969045368 0.877462799 0.920095147 0.942241932 Apoptosis 
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TNFRSF10B|8795 0.928498048 0.722229128 0.807584899 0.845447955 Apoptosis 
IRAK4|51135 0.850964937 0.407953414 0.542393434 0.576507065 Apoptosis 
AKT2|208 0.811729236 0.442267579 0.57384549 0.594253966 Apoptosis 
TP53|7157 0.781983264 0.317621325 0.451899412 0.488133505 Apoptosis 
TNFSF10|8743 0.781293076 0.702638858 0.794403205 0.838971771 Apoptosis 
CHUK|1147 0.761538351 0.19503154 0.31242497 0.325052566 Apoptosis 
CASP3|836 0.72174756 0.217893286 0.340947844 0.35574414 Apoptosis 
PPP3CB|5532 0.712740614 0.078592894 0.152898592 0.163309909 Apoptosis 
AIFM1|9131 0.675718708 0.088548547 0.167690744 0.170695994 Apoptosis 
CYCS|54205 0.668468007 0.083788996 0.160664505 0.165509128 Apoptosis 
RELA|5970 0.660513234 0.28637487 0.418594833 0.444854167 Apoptosis 
TNFRSF1A|7132 0.6303822 0.03826975 0.085839801 0.088741449 Apoptosis 
CASP9|842 0.615013855 0.214045046 0.336346338 0.353063994 Apoptosis 
PIK3R1|5295 0.614513493 0.041206331 0.091154035 0.092859337 Apoptosis 
PRKAR1A|5573 0.609609401 0.011095633 0.030716563 0.034650673 Apoptosis 
XIAP|331 0.56685483 0.005973984 0.018414361 0.021240833 Apoptosis 
IRAK1|3654 0.463666898 0.009453425 0.026885244 0.030250961 Apoptosis 
PIK3CD|5293 0.381720587 0.003158346 0.010777138 0.012325253 Apoptosis 
DFFB|1677 0.379813205 0.000668203 0.002853953 0.003144485 Apoptosis 
BCL2L1|598 0.363098051 0.001435298 0.005506771 0.006379102 Apoptosis 
CASP10|843 0.360988629 0.001282598 0.005015545 0.005863306 Apoptosis 
IL1A|3552 0.327784688 1.17E-06 1.04E-05 1.17E-05 Apoptosis 
CASP8|841 0.302178695 9.55E-09 1.33E-07 1.39E-07 Apoptosis 
PIK3R5|23533 0.251195017 0.0203725 0.050986098 0.056199999 Apoptosis 
BAX|581 0.233032518 5.87E-06 4.50E-05 4.70E-05 Apoptosis 
TIMP3|7078 3.807469864 4.97E-05 0.000297352 0.00032103 p53 
CDK2|1017 2.320657916 0.000397915 0.001825975 0.001989575 p53 
PCNA|5111 2.187994451 0.001682802 0.006313055 0.007047907 p53 
CDKN1A|1026 1.242686496 0.466095373 0.595617163 0.606302925 p53 
RB1|5925 1.216359365 0.320337612 0.454773083 0.488133505 p53 
CDK4|1019 1.068061553 0.867546058 0.912416713 0.942241932 p53 
CCND1|595 0.979846591 0.935851731 0.958009472 0.977464002 p53 
MDM2|4193 0.956158011 0.821050083 0.881830963 0.899780913 p53 
E2F1|1869 0.847764335 0.781888716 0.853935864 0.882594738 p53 
CCNE1|898 0.822984104 0.360058513 0.496061983 0.543484548 p53 
GADD45A|1647 0.626866347 0.083653584 0.160475787 0.165509128 p53 
Table 2.3: List of differentially expressed apoptosis and p53-related genes between Tera-1 and 
Tera-2 cells. 
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CHAPTER 3: DISCUSSION 
Despite intensive research for almost two decades, CAR-T therapy for solid tumors has yet to 
match the success rates of the CD19.CAR-Ts for leukemia/lymphoma patients (152). There are several 
major obstacles, both in the design process as well as after infusion into patients, that limit CAR-T 
therapeutic efficacy. Our data support the use of CD30.CAR-Ts as a novel and effective form of 
immunotherapy against EC, in particular the relevance of Fas/FasL interactions for CAR-T targeting of 
solid tumors. The limitations of CD30.CAR-T therapy will also be discussed, as well as several 
engineering strategies to improve CD30.CAR-T anti-tumor efficacy. 
3.1 CD30 is an ideal EC antigen to target by CAR-T therapy 
 A major challenge in targeting solid tumors by CAR-T therapy is the limited number of candidate 
antigens, as many tumor-associated antigens are also shared with normal tissues (153). The ideal target 
antigen should: a) be expressed at the cell surface at sufficient levels to be recognized by the CAR, b) be 
expressed in most tumor cells, especially cancer stem cells which are a tumor subpopulation that 
contributes to relapse (132) and c) be expressed in a sufficient number of patients with little to no 
expression in essential normal tissues (154). Choosing appropriate target antigens is critical for safety, as 
toxicities related to “on-target off-tumor” effects due to improper CAR-T activation against normal 
tissues have limited further treatment in patients (155). In an extreme case, a patient with colon cancer 
that metastasized to the lungs and liver who was treated with ERBB2-specific CAR-Ts developed acute 
respiratory distress syndrome due to low-level ERBB2 expression in lung tissue and died five days after 
the initial infusion (156). These symptoms are mechanistically linked to elevated levels of IL-6 and IFN-γ 
released by innate immune cells and infused T cells, respectively, termed cytokine release syndrome 
(CRS) (155). 
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Based on these criteria, CAR-Ts have been designed to target classes of antigens: a) Antigens 
with novel peptide sequences due to gene mutation or posttranslational modifications (neoantigens), such 
as EGFRvIII or glycosylated MUC1, b) antigens which are normally expressed only during fetal 
development or at immunoprivileged sites, such as CEA or cancer-testis antigens like NY-ESO-1, or c) 
antigens expressed at higher than normal levels on tumor cells compared to non-malignant host cells, such 
as mesothelin (152). Although neoantigens are most ideal for CAR-T targeting because they are 
exclusively expressed by tumor cells, these antigens are typically unique to individuals and are generally 
not scalable for multiple patients (157).  
CD30 is an ideal target for CAR-T immunotherapy against ECs, as it is highly expressed on ECs 
both at diagnosis and after disease progression (108). Although the function of CD30 in ECs is unclear, 
Herszfeld et al. specifically linked CD30 expression to enhanced tumorigenic features among transformed 
hematopoietic stem cells (87), and we show that CD30 is also expressed on EC cells with stem cell-like 
properties. Furthermore, CD30 expression in TGCTs is correlated with worse outcomes, such as increased 
rates of metastasis and decreased progression-free survival (108); therefore, patients with increased risk of 
disease progression are also likely to benefit from CD30-targeted therapy. Promising results have been 
reported using brentuximab vedotin in relapsed TGCT patients enrolled in clinical studies (110;130). In 
our preclinical study using CD30+ ECs, we show that CD30.CAR-Ts can selectively target both 
differentiated and stem cell-like EC cells, reducing the chance of relapse. 
3.2 CD30.CAR-Ts utilize Fas/FasL interactions to target ECs with heterogeneous antigen 
expression 
Tumor cells can escape CAR-T targeting either in an indirect manner due heterogeneous 
expression of the target antigen in a subpopulation of cells, such as EGFRvIII in glioblastoma (158), or in 
a direct manner by downregulating targeted antigens (159;160) or modifying antigens (73) to escape 
immune surveillance. In the past, one strategy to overcome tumor escape has been to target more than one 
antigen present on tumor cells. For example, CAR-Ts targeting two different antigens, but where one 
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receptor bears only the CD3ζ endodomain and the other contains only the co-stimulatory endodomain, has 
been used to generate an optimal anti-tumor response only in the presence of both antigens (161;162). 
Alternatively, CAR-Ts which contain two different extracellular receptors fused together (tandem CARs) 
or as separate receptors (bispecific CARs) have been designed to prevent tumor escape by antigen 
downregulation (163). Specific examples include the CD19/CD20 bispecific CAR-Ts for B cell 
lymphoma (135) and HER2/IL13Rα2 bispecific CAR-Ts (164) or tandem CAR-Ts (165) for 
glioblastoma. However, the configuration of the extracellular receptor could impact the efficacy of these 
bispecific CAR-Ts, and optimal designs are still empirically determined (154).  
We show that Fas-FasL interaction between ECs and CD30.CAR-Ts may represent a novel way 
to overcome tumor escape associated with antigen heterogeneity. Specifically, in Tera-1 cells with Fas+ 
expression and a mixed population of CD30+ and CD30– cells, we show that both fractions are eliminated 
upon CD30.CAR-T activation. This phenomenon is consistent with known observations that TGCTs are 
highly susceptible to chemotherapy agents, which induce cell death via the death receptor pathways 
(166;167). Others have subsequently shown that EC upregulates Fas downstream of p53 in response to 
cisplatin chemotherapy (168), showing a direct link between chemotherapy susceptibility and Fas 
signaling. Fas/FasL signaling is also important for drug-induced apoptosis in multiple cancers such as 
leukemia (169), neuroblastoma (170), and hepatoma (171). Therefore, it is plausible that CAR-Ts can 
utilize FasL to target multiple cancers with heterogeneous antigen expression. 
3.3 CD30.CAR-Ts introduce Fas/FasL interactions in a localized manner 
An important mechanism by which cytotoxic T lymphocytes (CTLs) induce cell death is the 
engagement of Fas ligand and TNF-related apoptosis-inducing ligand (TRAIL) with their corresponding 
death receptors Fas, DR4, and DR5 on tumor cells (172). Specifically, upon ligand binding the death 
receptors stabilize into complexes, induce activation, and recruit adaptor proteins to form the death-
inducing signaling complex (DISC), the activation platform for pro-caspase-8 and subsequent cleavage of 
caspases 3, 6, and 7 (137;173). In a similar manner, granzyme B/perforin lytic granules secreted by CTLs 
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can also trigger apoptotic and/or necrotic cell death through caspases 3 or 7 (174). Granzyme B can also 
induce cell death in a caspase-independent manner by altering mitochondrial membrane permeability 
(174). Granzyme A, the other primary granzyme secreted by CTLs, induces cell death by cleaving SET, 
leading to single-strand DNA breaks with inhibition of DNA repair (175). To augment tumor cell death, 
multiple investigators have targeted the Fas/FasL pathway but these therapies had severe toxicities 
limiting their clinical use. For example, the Fas agonistic antibody Jo2 or RK-8, was efficient in killing 
tumor cells but also resulted in extensive liver damage due to both direct and indirect effects on 
hepatocyte cell death (176;177). 
We observe that CD30.CAR-Ts, upon activation by receptor engagement, selectively upregulates 
FasL expression and targets both CD30+ and CD30– EC cells in a contact-dependent manner. Specifically, 
while CD30.CAR-Ts eradicate CD30+ EC cells via perforin/granzyme B-mediated mechanisms, they also 
eliminate surrounding CD30– tumor cells, if they express the CD95 molecule, via caspase 3 activation. 
Therefore, in contrast to systemic antibody treatment, CD30.CAR-Ts engage in localized Fas/FasL 
interactions and may represent a safer alternative.  
Nevertheless, tumor cells can also downregulate Fas expression as a mechanism of immune 
escape. For example, reduced Fas expression has been previously reported in colon carcinomas in part 
due to DNA hypermethylation of a CpG-rich region within the Fas promoter (142). Fas mutations have 
also been described in 62.5% of EC lesions (144). The NCCIT cell line is an example of a resistant tumor 
cell line that show Fas downregulation, possibly due to its expression of a mutant p53 which is non-
functional (178). Our RNA-Seq data also suggest that NCCIT cells have decreased expression of p53 
compared to the EC cell lines Tera-1 and Tera-2, with corresponding decreased expression of apoptosis-
related genes. Nevertheless, we demonstrate that inducing Fas overexpression in NCCIT cells is sufficient 
to improve CD30.CAR-T anti-tumor activity. These results suggest that the downstream Fas signaling 
transduction pathway is intact in NCCIT cells, and that Fas/FasL interactions can be manipulated to 
improve CD30.CAR-T targeting even at low E:T ratios.  
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3.4 Improvements to CD30.CAR-Ts for optimal T cell trafficking and persistence in vivo 
 CAR-Ts, similarly to other T cell therapies, show limited persistence after infusion not only in 
pre-clinical models like what we observed, but also in phase I clinical trials. For example, HER2-specific 
CAR-Ts did not expand after infusion in the peripheral blood, though cells trafficking to the tumor site 
could be detected at low levels for more than 6 weeks (77). In a clinical trial using FR CAR-Ts for 
ovarian cancer, T cells were undetectable in the blood but persisted at low levels in tumors (70). For GD2 
CAR-Ts, the duration of persistence was shown to be associated with the percentage of CD4+ cells and 
central memory cells (CD45RO+CD62L+) in the infused product (78). Even among the CAR-Ts that show 
long-term persistence, multiple factors can prevent optimal T cell trafficking to the tumor site, such as 
decreased expression of appropriate chemokine receptors (56;179) or physical barriers such as abnormal 
vasculature (180) or collagen (181).  
To both improve CAR-T anti-tumor activity and avoid systemic toxicity with intravenous 
delivery, some investigators have performed intratumoral administration of T cells. For example, 
intracranial delivery of the IL13-zetakine CAR-Ts for recurrent glioblastoma resulted in transient anti-
glioma responses was observed in 2 out of 3 patients as well as increased tumor necrosis at the site of T 
cell administration (182). Intrahepatic delivery of CEA-directed CAR-Ts through percutaneous hepatic 
artery infusions for liver metastasis was also well-tolerated (183). Other investigators are engineering new 
delivery mechanisms, such as implantable biopolymer devices (184) that bring CAR-Ts directly to the 
surface of the tumor site. 
CAR-Ts have also been modified to support T cell trafficking and persistence in vivo. Co-
transduction of CAR-Ts with appropriate chemokine receptors enhances T cell localization and anti-
tumor activity, such as CCR2 for CCL2-secreting malignant pleural mesotheliomas (185) or 
neuroblastoma (179). CAR-Ts engineered to express heparanase, the only known mammalian enzyme to 
cleave heparan sulphate proteoglycans and otherwise downregulated among in vitro cultured CAR-Ts, 
showed improved tumor infiltration by ECM degradation and enhanced CAR-T anti-tumor activity (118). 
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CAR-Ts expressing the pro-survival cytokine IL-15 show greater expansion, decreased PD-1 expression, 
and improved anti-tumor activity (146). More recently, investigators showed that CAR-Ts expressing IL-
18 have a T-bethi FOXO1lo pro-inflammatory effector phenotype with enhanced anti-tumor activity 
against pancreatic cancers (186) and melanoma (187). Nishio et al. (145) combined CAR-T cells with an 
oncolytic adenovirus armed with the chemokine RANTES and the cytokine IL-15 to improve tumor cell 
killing, CAR-T cell migration and overall survival in a mouse model of neuroblastoma without overt 
toxicities to CAR-Ts. An intriguing application of our results would be to engineer oncolytic viruses to 
selectively induce high levels of Fas in tumor cells, which would synergize with CAR-T therapy to 
promote both antigen-dependent CAR-mediated and antigen-independent Fas/FasL mediated elimination 
of tumor cells.  
 Alternatively, combining T cell therapy with other treatment modalities such as peripheral 
immune checkpoint blockade or oncolytic viruses may create a synergistic anti-tumor response. For 
example, therapeutic PD-1 or PD-L1 blockade shows favorable responses in patients with pre-existing 
TILs that are otherwise negatively regulated by PD-1/PD-L1 mediated adaptive resistance (188;189). In 
the first phase I clinical trial combining CAR-T cell therapy with PD-1 inhibition, lymphodepletion prior 
to CAR-T therapy resulted in increased circulating levels of IL-15 & CAR-T expansion but surprisingly 
PD-1 inhibition did not further enhance expansion or persistence (190). PD-L1 is highly expressed in 
some EC tumors (148), and in a case study one EC patient was reported to respond to anti-PD-1 therapy 
(43). While PD1/PD-L1 blockade as single agents may not be effective in TGCTs due to its low mutation 
rates (149), these inhibitors may prevent the exhaustion of CD30.CAR-Ts that express PD1 upon 
activation (150). 
In conclusion, we demonstrate that CD30.CAR-Ts represent a clinically applicable strategy in 
patients with ECs, who are at increased risk of relapse after chemotherapy and who otherwise have 
limited treatment options. CD30.CAR-Ts target both differentiated and stem cell-like EC cells. We also 
show that CD30.CAR-Ts, upon antigen engagement, upregulate FasL to enhance CAR-T cytolytic 
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activity against antigen-expressing cells while also countering tumor escape due to heterogeneous antigen 
expression (Fig.3.1). More broadly, CD30.CAR-Ts could be used to target other CD30-expressing solid 
tumors, such as neoplasms with chondroid differentiation (151).  
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Figure 3.1: Model for CD30.CAR-Ts targeting both CD30+ and CD30– EC cells. CD30.CAR-Ts 
become activated by engagement of its extracellular receptor with CD30, initiating tumor cell death by 
both upregulation of FasL and of granzyme B/perforin. CD30– EC cells are targeted by activated 
CD30.CAR-Ts through Fas/FasL interactions at the cell surface. 
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APPENDIX 1: EPIGENETIC DYSFUNCTION IN TURNER SYNDROME IMMUNE CELLS 2 
 
Introduction  
Turner Syndrome (TS) is a common chromosomal abnormality, occurring in about 1:4000 live 
births, which describes phenotypic females with either partial or complete absence of one sex 
chromosome (191). TS in named for Dr. Henry Turner who in 1938 published his study describing seven 
women with short stature, sexual immaturity, cubits valgus, webbed neck and low posterior hairline 
(192). In the mid 1950s, advances in cytogenetic identification of chromosomes discovered that patients 
with TS were missing an X chromosome (193). The absence of this sex chromosome results in 
characteristic TS clinical findings: short stature, webbed neck, lymphedema of hands and feet, ovarian 
failure and recurrent otitis media (Table 1) (194). 
In non-Turner 46 XX females, one copy of the X chromosomes is inactivated to achieve some 
degree of balanced gene expression between males and females. Thus, absence of one sex chromosome, 
on the surface, would not be predicted to have any effect. However, X-inactivation is incomplete. In 46 
XX females 15% of the genes on the silenced X chromosome escape inactivation and continue to be 
expressed from both chromosomes. Most genes escaping X-inactivation are pseudoautosomal genes 
located on the short arm of the X chromosome and have homologous genes on the Y chromosome. 
Therefore, most abnormalities seen in TS are thought to be due to haploinsufficiency of genes that are 
normally expressed by both X chromosomes (Fig. 1A) (191;195). 
In 1965, after analyzing hundreds of karyotypes of patients with various forms of gonadal 
dysgenesis, Dr. Malcolm Ferguson-Smith proposed that short stature and congenital malformations found 
in TS were due to gene deletions from the short arm of the missing X chromosome. He hypothesized that 
some genes on the silenced X chromosome escape inactivation (196). His observations were confirmed in 
                                                           
2 This appendix previously appeared in the journal Current Allergy and Asthma Reports. The original citation is as 
follows: Thrasher B, Hong LK, Whitmire JK, Su MA. “Epigenetic Dysfunction in Turner Syndrome Immune Cells.” 
Curr Allergy Asthma Rep 2016 May;16(5):36. 
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future chromosomal banding and molecular studies with the identification of the short stature homeobox-
containing gene (SHOX). SHOX is a pseudoautosomal gene that escapes X-inactivation and is highly 
expressed in osteogenic tissue. Haploinsufficiency for SHOX in TS is the major contributor to growth 
failure in TS (197).  
Knowledge of TS has increased exponentially since it was first described in 1938. With better 
recognition and routine health exams physicians are able to treat some of the comorbidities associated 
with TS, such as growth failure and ovarian insufficiency. However, there is still much to be learned 
about other comorbidities associated with TS, particularly immune abnormalities. This review will 
discuss the current literature regarding TS and associated immune abnormalities and will highlight the 
role of a pseudoautosomal gene recently discovered to affect CD4+ T cells’ ability to clear chronic viral 
infection.  
  
Turner Syndrome is associated with immune abnormalities  
In addition to the wide array of anatomical and physiological features and comorbidities, TS 
patients have a predisposition to immune mediated diseases, including chronic otitis media (OM). The 
pathogenic mechanism underlying this susceptibility to otitis media is unclear. One hypothesis is that 
craniofacial features of TS predisposes to chronic OM (198). Another hypothesis is that an underlying 
immune deficiency may be a component of TS and contribute to chronic otitis media. Consistent with this 
latter possibility, TS patients have abnormal immune alterations in T cell and immunoglobulin subsets, 
reduced levels of serum IgG and IgM, increased IgA and decreased levels of circulation T and B 
lymphocytes (199-201). However, these findings are not conclusive, as other studies looking for immune 
abnormalities in TS subjects did not find major immunological deficiencies (202-204).  Thus, some 
though not all studies suggested that TS subjects might have an immune deficiency that predisposes to 
chronic OM.   
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TS patients have decreased expression of UTX, a histone modifying enzyme  
Based on the underlying genetic basis for TS, it is likely that immune deficiencies in TS are 
primarily due to direct effects of haploinsufficient X-chromosome genes. To screen for candidate genes 
that are haploinsufficient in TS patients, Cook et al. performed a microarray analysis on peripheral blood 
mononuclear cells (PBMCs) comparing control females to TS subjects with confirmed 45X karyotype 
(205). 1169 unique genes showed differential expression, including 35 on the X chromosome. In 
particular, Ubiquitously Transcribed Tetratricopeptide repeat on chromosome X (UTX, encoded by Utx 
or Kdm6a located at Xp11.3 (206)) was among the top 10 genes with the largest decrease in expression 
and the only gene among these candidates that escapes X-inactivation (207). 
UTX is a histone modifying protein that epigenetically regulates expression of its target genes. 
Epigenetics refers to any process that causes changes in gene expression without changes in the DNA 
sequence (208). For this review, we will focus on chromatin modifications as epigenetic mechanisms of 
regulation (209). Chromatin, the condensed packaging of DNA, consist of nucleosomes that contain 146 
base pairs of DNA tightly wound around histones (210). These histones contain amino acid residues on 
“tails” exposed around the nucleosome core that can be biochemically modified, such as methylation, 
acetylation, and phosphorylation, to alter gene expression. Histone H3 lysine 27 trimethylation 
(H3K27me3) is a repressive modification typically found in heterochromatin or transcriptionally silenced 
loci. H3K27 methylation status is enzymatically regulated by methyltransferases, such as Ezh2, that adds 
methyl groups to suppress transcription of its target genes (211). Conversely, the Jumonji D3 (Jmjd3) 
family of H3K27 demethylases, comprising of Jmjd3 and UTX, remove methyl groups and enable gene 
expression (Fig. 1B) (212). 
  UTX, as the name implies, is ubiquitously expressed and plays a major role in several cell 
processes, such as embryonic development (213;214), cell cycle regulation (215), hematopoiesis (216), 
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and cancer pathogenesis (217;218). Of note, genetic deficiency of either the KMT2D gene or the UTX 
gene results in the genetic disorder Kabuki syndrome (KS), a rare congenital disorder that is also 
associated with immune abnormalities such as recurrent OM (205;206), reduced immunoglobulin levels, 
hypogammaglobulinemia, poor vaccine response and reduced memory T and B lymphocytes (219;220) 
These clinical findings suggest that UTX may also be critical for regulating T cell development and/or 
immune function. 
  
UTX regulates T follicular helper cell (Tfh)-mediated clearance of chronic viral infection  
Naïve CD4+ T cells, upon antigenic stimulation, become activated and can differentiate into 
several T helper subsets depending on the local cytokine milieu. To achieve this carefully orchestrated 
immune response, differentiating CD4+ T cells upregulate a specific subset of genes, such as subset-
defining transcription factors and effector molecules, and repress non-subset specific genes (210). This 
epigenetic “framework” allows both flexibility for naive T cells to differentiate into multiple unique 
subsets as well as specificity in gene expression (221). During chronic viral infection, T follicular helper 
(Tfh) cells, in particular, are critical for generating an appropriate B cell antibody response. Tfh cells were 
initially described as a CXCR5hi CD4+ T cell subset within human tonsils, lymphoid tissues that are 
subjected to high antigenic burden from both nonpathogenic and pathogenic exposures (222). Within 
follicles of secondary lymphoid tissues, B cells require CXCR5 expression to migrate to germinal centers 
(GCs) as sites of B cell maturation; thus, T cell expression of CXCR5 enables Tfh cells to co-localize 
with B cells. Tfh-B cell interactions through T cell receptor-major histocompatibility complex class II 
(TCR-MHCII) engagement and through signaling proteins, such as SAP, CD40-CD40L and ICOS, 
promote B cell somatic hypermutation, class switching and IgG antibody formation (223-226).  
Importantly, murine and human Tfh surface markers and master transcription factor expression of B-cell 
lymphoma 6 (Bcl6) is highly conserved (222), making mouse models of chronic infection an ideal model 
to study Tfh function.  
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  Several human genetic immunodeficiencies have revealed an important role for Tfh cells in 
clearing viral infection. For example, X-linked lymphoproliferative disease (XLP) patients with a Sh2d1a 
genetic mutation resulting in loss of SAP expression are at a profound increased risk for Epstein-Barr 
Virus infections and have nearly absent GCs (222). In addition, Tfh deficiency has been associated with 
poor neutralizing antibody response in chronic viral infections like HIV (227). Finally, otitis-prone 
children following infection displayed reduced cytokine-secreting memory T cells and a poor IgG 
response relative to children not prone to OM, suggesting poor T cell help to B cell antibody responses in 
children with chronic OM (228). Understanding how Tfh cell differentiation and function is regulated, 
therefore, is critical for boosting the anti-viral immune response.  
  Cook et al recently demonstrated that UTX supports T follicular helper cells (Tfh cells) that are 
needed for B cell antibody generation during chronic viral infection (205). Mice with a conditional UTX 
deficiency in T cells (UTX-TCD mice) showed normal clearance of acute viral infection but elevated 
viral titers after chronic viral infection that persisted even after clearance by control mice. This impaired 
immunity to chronic viral infection was associated with decreased Tfh cells, fewer germinal centers, and 
impaired virus-specific IgG production. Mechanistically, UTX is required for proper Tfh differentiation 
and the induction of Tfh-specific gene expression, such as ICOS and SLAMF6, while inhibiting Th1-
specific gene expression. In UTX-deficient Tfh cells, decreased gene expression corresponded to 
increased H3K27 methylation status for the majority of Tfh-specific genes, consistent with decreased 
demethylase activity. Finally, mice that are heterozygous for T cell-specific UTX deficiency show 
partially attenuated viral loads, suggesting that UTX function for Tfh-dependent clearance of chronic viral 
infection is dose dependent (205).  
  
TS patients have decreased Tfh cells which may increase predisposition to chronic OM  
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Overall, these data suggest that UTX may be haploinsufficient in TS patients with functional 
consequences for Tfh-dependent clearance of chronic OM. To test whether UTX deficiency results in Tfh 
cell deficiency in TS subjects, total naïve (CD45RA+), antigen-experienced (CD45RO+) CD4+ cells and 
CD4+CXCR5+ cells were measured.  In humans, CD4+CXCR5+ cells in peripheral blood have been 
associated with antibody production, which allows them to serve as a measurable substitute of Tfh (229).  
No significance was noted in total, naïve and antigen-experienced CD4+ T cells between TS subjects and 
controls.  However, the frequency of CD4+ CXCR5+ T cells were reduced by 2-fold in TS subjects 
compared to controls (205). This suggests that decreased UTX expression in TS patients might increase 
their predisposition to viral infections due to Tfh cell deficiency.  
  
UTX may also affect other T cell subsets in a demethylase-dependent and independent manner  
In addition to its H3K27 demethylase activity, UTX can also regulate gene expression in a 
demethylase-independent manner through protein interactions with chromatin remodeling complexes, 
such as Brg1, and transcriptional protein complexes. For example, UTX interacts with Th1-specific 
transcription factor T-bet and the Brg1-containing SWI/SNF remodeling complex in primary human T 
cells to upregulate interferon-gamma (Ifng) expression (230). Interestingly, siRNA inhibition of UTX 
with transfection of a demethylase-inactive mutant rescued chromatin remodeling at the Ifng promoter 
similarly to demethylase-sufficient UTX (230). In embryonic development, UTX deficiency in male mice 
can be compensated by UTY, a homologue of UTX expressed on the Y chromosome but with no 
demethylase activity (214;231). Furthermore, the development of male embryos deficient in both UTX 
and Jmjd3, and therefore all known H3K27me3 demethylase activity, was similar to that of embryos 
lacking Jmjd3 alone (231).  Therefore, UTX demethylase activity is dispensable for embryonic 
development. 
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Recent work demonstrated that UTX may play an important role in T cell differentiation and 
effector functions. For example, T cell-specific UTX and Jmjd3-deficient mice showed increased 
numbers of CD4SP mature thymocytes but decreased peripheral T cell numbers (232). This effect was 
due to increased H3K27me3 with corresponding decreased expression of S1PR1, the sphingosine receptor 
required for mature thymocytes to exit the thymus (232). Furthermore, demethylase-defunct UTY failed 
to rescue CD4SP thymocyte S1PR1 expression in UTX and Jmjd3-deficient males, supporting the notion 
that H3K27 demethylase activity directly results in S1PR1 expression. Deficiency in either UTX or Jmjd3 
alone in CD4+ T cells resulted in a milder phenotype, suggesting that UTX and Jmjd3 have overlapping 
H3K27 demethylase activity (232). Conversely, ChIP-Seq experiments in UTX-deficient T cells reveal 
several gene loci for which gene expression is different relative to controls but no H3K27 methylation 
changes were detected (205;232). Overall, UTX demethylase function is highly gene-specific – as in, 
specifically targets the gene expression of a select number of genes rather than regulate global 
H3K27me3 homeostasis - but also has demethylase-independent activity critical for its function in vivo. 
Whether UTX regulates other T cell subsets important for viral clearance, such as CD4+ Th1 cells or 
CD8+ cytotoxic T cells, is unknown.  
  
Conclusions and future directions  
TS association with autoimmune diseases and chronic otitis media suggest that TS patients have 
abnormal immune alterations in T cell and immunoglobulin subsets. However, studies looking for 
immune abnormalities are inconclusive. Most recently postulated as to why TS patients are predisposed to 
chronic viral infections is reduced expression of UTX, which serves as an epigenetic modulator in T cell 
development. This suggests that TS subjects have aberrant regulation of immune pathways, which 
increases their susceptibility to infections. Mechanistically UTX can explain why TS subjects have 
recurrent OM, but it doesn’t explain why TS patients are an increased risk of autoimmune diseases such 
as hypothyroidism and celiac disease. In regards to autoimmunity, TS patients are believed to have 
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defective regulatory T cells (Tregs) that fail to inhibit proliferation of effector T cells (204). On the other 
hand, a different study showed no difference in Treg frequencies or function in TS patients (233). The 
mechanism underlying defective Tregs remains elusive. Recently, DNA methylation patterns, another 
epigenetic modification, of multiple autosomal genes involved in bone remodeling, glucose sensitivity 
and ovarian function have been reported to be altered in TS (234). Thus, it is feasible that multiple 
epigenetic mechanisms of gene regulation are dysregulated in TS.  
  From a therapeutic viewpoint, no pre-scheduled program of immune surveillance for TS patients 
has been recommended. Large-scale studies evaluating immunoglobulin levels, T and B cell lymphocytes 
at different time intervals are needed to determine if an immune surveillance schedule is warranted. If TS 
subjects are found to have immune alterations, treatment with IVIG supplementation and frequency of 
infections will need to be analyzed. Also, clinical studies evaluating the immune response in TS patients 
to chronic viral illnesses and vaccines are needed to evaluate for immune alterations. Even though more 
work needs to be done in the field of immunity and TS, the discovery of UTX as a gene with decreased 
expression in TS and the mechanism by which UTX affects T cell differentiation is an important step in 
developing new therapeutic opportunities correcting immune alterations at the cellular level.        
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Figure 1. (A) TS patients are haploinsufficient in pseudoautosomal genes. Because pseudoautosomal 
genes escape inactivation, they are expressed from 2 copies of the X chromosomes in 46XX females. 
They are also expressed on the Y chromosome, so are expressed from 2 copies in 46XY males. In 45XO 
TS females, however, they are only expressed from 1 X chromosome, so may be haploinsufficient in TS. 
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(B) Model: UTX deficiency in TS patients predisposes to chronic viral infection due to impaired Tfh 
differentiation. In 46XX females haplosufficient for UTX, Tfh cells differentiate from naïve CD4+ T cells 
through UTX-specific H3K27 demethylase activity. H3K27 demethylation results in increased expression 
of Tfh-specific genes and adequate Tfh help for B cell maturation, anti-viral antibody production, and 
viral clearance. However, in TS patients and in UTX-deficient mice, UTX haploinsufficiency results in 
decreased circulating Tfh cells due to H3K27 methylation and transcriptional suppression of Tfh-specific 
genes. 
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Characteristics  Prevalence (%)  
Growth Abnormalities  
• Short Stature  
• Small for Gestational Age at Birth  
90  
Reproductive Abnormalities  
- Ovarian Failure   
90  
Dermatologic Abnormalities   
• Multipe Pigmented Nevi  
• Lymphedema of the extremities  
• Vitiligo  
• Alopecia  
70  
Neck Abnormalities  
• Webbed Neck  
• Low Posterior Hairline  
70  
Chest Abnormalities  
• Shield Chest  
• Wide Spaced Nipples  
70  
Otologic Abnormalities   
• Otitis Media  
• Hearing Loss – Conductive or Sensorineural  
50  
Renal Abnormalities  
• Horseshoe Kidney  
• Renal Agenesis  
50  
Cardiovascular Abnormalities  
• Coartation of the Aorta  
• Hypertension  
• Bicuspid Aortic Valves  
50  
Skeletal Abnormalities  
• Short 4th Metacarpals  
• Madelung Deformities  
• Cubitus Valgus  
50  
Endocrine Abnormalities  
• Autoimmune Hypothyroidism  
• Carbohydrate Intolerance  
50  
Gastrointestinal Abnormalities  
• Fatty Liver Disease  
• Celiac Disease  
30  
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Table 1: Characteristics and Comorbidities in Turner Syndrome. Clinical characteristics of TS 
patients with prevalence are shown. Immune complications are highlighted in bold. Characteristics 
secondary to lymphatic obstruction are italicized. 
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APPENDIX 2: COMBINATION CENTRAL TOLERANCE AND PERIPHERAL CHECKPOINT 
BLOCKADE UNLEASHES ANTI-MELANOMA IMMUNITY3 
 
Introduction 
Augmenting endogenous anti-melanoma T cell responses through blockade of immune 
checkpoints has proven effective as a therapeutic strategy against metastatic melanoma (235). 
Ipilimumab, a monoclonal antibody targeting the co-inhibitory immune checkpoint protein CTLA-4 on T 
cells, was the first systemic treatment to show prolonged overall survival in patients with metastatic 
cutaneous melanoma (236). However, aCTLA-4 antibody provides disease control in only 22% of 
patients (236;237), with long-term benefit in <10% of patients (236;238). Thus, for most metastatic 
melanoma patients, the anti-melanoma T cell response after CTLA-4 blockade continues to be 
inadequate. Since the approval of ipilimumab by the FDA in 2011, two other immune checkpoint 
inhibitors, which target the co-inhibitory immune checkpoint protein PD-1, have been approved on the 
basis of randomized clinical studies (239-241). Despite improved efficacy with treatments targeting PD-1, 
many patients still have only transient responses or do not respond to these therapies. What constrains the 
anti-melanoma effects of checkpoint inhibitors is currently unclear (242).  
Central T cell tolerance mechanisms protect against the development of autoimmunity, but also 
limit anti-tumor immunity (243-245). A key mediator of central tolerance is the Autoimmune Regulator 
(Aire) gene, a transcriptional activator expressed predominantly in medullary thymic epithelial cells 
(mTECs). There, Aire promotes expression of tissue-restricted self-antigens (TSAs), so that self-reactive 
thymocytes that recognize these TSAs with high affinity undergo negative selection. A subset of Aire-
regulated TSA’s is expressed by both melanocytes and melanoma cells. As a consequence, while purging 
self-reactive T cells that recognize melanocyte antigens, Aire also removes T cells capable of recognizing 
                                                           
3
 This appendix previously appeared in the Journal of Clinical Investigation Insight. The original citation is as 
follows: Bakhru P, Zhu M, Wang H-H, Hong LK, Khan I, Mouchess M, Gulati A, Starmer J, Hou Y, Sailer D, Lee 
S, Zhao F, Kirkwood JM, Moschos S, Fong L, Anderson MS, Su MA. “Combination central tolerance and 
peripheral checkpoint blockade unleashes antimelanoma immunity.” JCI Insight 2017;2(18):e93265. 
77 
 
and eradicating melanoma cells. In humans, protection from melanoma has been associated with distinct 
AIRE single nucleotide polymorphisms (SNPs), which can decrease stability of Aire mRNA (246). This 
protection is associated with increased frequency of T cell clones recognizing MAGE-1, a self/melanoma 
antigen expressed in the thymus. Together, these findings support a model in which Aire deficiency 
prevents deletion of T cell clones that recognize self/melanoma antigens to promote a more robust T cell-
mediated anti-tumor response.   
While Aire limits anti-melanoma immunity through its function in the thymus, CTLA-4 and other 
checkpoint proteins limit T cell responses through their activity in the immunologic periphery (247). 
Upon T cell receptor (TCR) activation, T cells upregulate checkpoint proteins that attenuate the T cell 
response (248). CTLA-4, for example, dampens early T cell activation by inducing inhibitory downstream 
T cell receptor signaling and competitive inhibition of CD28-mediated coactivation. The distinct 
mechanisms of actions of Aire and checkpoint proteins led us to hypothesize that blockade of central 
Aire-mediated tolerance may interact with blockade of peripheral checkpoint inhibition to enhance T cell 
mediated anti-melanoma immunity. 
We report here that Aire deficiency and anti-CTLA-4 (aCTLA-4) antibody in combination have 
an additive effect in diminishing melanoma outgrowth and prolonging survival in melanoma-bearing 
mice. A pool of melanoma-reactive, cytolytic CD4+ T cells that escape thymic deletion in the setting of 
Aire deficiency are further activated by checkpoint inhibition in the periphery, leading to enhanced anti-
tumor effect. Additionally, combination therapy using pharmacologic depletion of Aire-expressing 
mTECs (249), and inhibition of CTLA-4 significantly prolonged survival in melanoma-bearing mice 
compared to either strategy alone. Finally, an Aire single nucleotide polymorphism (SNP) (rs1055311) is 
associated with response to ipilimumab therapy in metastatic melanoma patients, as part of the E1608 
clinical trial (250).  These findings point to Aire-mediated central tolerance as a key mechanism limiting 
the efficacy of checkpoint inhibitors and provide pre-clinical evidence for combining central and 
peripheral tolerance blockade to expand the anti-tumor immune response.  
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Results 
Aire deficiency enhances anti-melanoma effects of CTLA-4 blockade in mice. A dominant 
Aire G228W mutation results in partial loss of Aire function (251), and mice with one copy of this 
mutation (AireGW/+ mice) have increased anti-melanoma immunity (245). We used AireGW/+ mice to test 
the hypothesis that Aire deficiency and peripheral checkpoint inhibition have additive effects in 
increasing anti-melanoma immunity. CTLA-4 is a co-inhibitory immune checkpoint protein induced by T 
cell activation. In Aire-sufficient (WT) mice challenged with B16 melanoma, aCTLA-4 antibody 
administration did not alter melanoma growth or host survival (Figure 1A and B), a finding consistent 
with previous reports (252;253). In AireGW/+ mice, on the other hand, aCTLA-4 antibody decreased 
melanoma growth and improved host survival compared to isotype control (Figure 1A and B). These 
results suggest that Aire deficiency and aCTLA-4 antibody administration in combination have additive 
effects in decreasing B16 melanoma growth and improving host survival.  
Human Aire polymorphism is associated with response to aCTLA-4. We investigated 
whether the interaction between Aire deficiency and aCTLA-4 antibody in melanoma-bearing mice might 
also have relevance in melanoma patients. Monoclonal aCTLA-4 IgG1 (ipilimumab) was the first 
checkpoint inhibitor to obtain FDA approval for patients with advanced melanoma. However, only 10-
20% of patients respond to treatment (236;254;255), and the factors that determine response are unclear. 
Multiple Aire polymorphisms, including one that may negatively affect mRNA Aire stability (246), have 
been associated with protection from melanoma development. This suggested that Aire polymorphisms 
that disrupt Aire function may enhance anti-melanoma immunity in humans. Based on our findings in 
mice, we sought to test whether Aire polymorphisms may be associated with response to ipilimumab. 
We focused on 5 Aire polymorphisms (rs1800522, rs2075876, rs56393821, rs1800520, 
rs1055311) that have previously been associated with melanoma protection. 79 patients with metastatic 
melanoma participating in the E1608 study, a randomized phase 2 study of ipilimumab versus ipilimumab 
plus GM-CSF (250), were genotyped for these 5 Aire polymorphisms. All 79 patients included in this 
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study were randomized to the ipilimumab-alone arm. The rs1055311 TT polymorphism, which has 
previously been associated with protection from melanoma development (246), was present in 6/79 
patients (7.6%). Presence of the rs1055311 TT polymorphism was associated with increased probability 
of progression free survival (Fisher’s exact test p=0.036; Figure 1C) and trend toward increased 
probability of overall survival, although this did not reach statistical significance [(log rank p=0.13); 
Figure 1D]. A caveat of these findings is the small number of patients harboring the rs1055311 TT 
polymorphism, which may reflect the melanoma-protective property of this SNP. These data suggest that 
this Aire SNP may be associated with response to ipilimumab in metastatic melanoma and should be 
validated in a larger scale study.  
CD4+ T cells from Aire-deficient mice have increased cytolytic capacity. We next sought to 
delineate the cellular mechanism underlying enhanced anti-melanoma immunity with combined Aire 
deficiency and CTLA-4 blockade. While it is known that Aire deficiency rescues melanoma-reactive 
CD4+ and CD8+ T cells from thymic deletion (244;245), whether enhanced anti-tumor immunity in Aire-
deficient mice is mediated by CD4+ or CD8+ T cells is unclear. To determine this, we purified CD4+ or 
CD8+ T cells from either AireGW/+ or WT littermates and transferred these cells into immunodeficient 
RAG−/− recipients. Recipients were then inoculated with syngeneic B16 melanoma cells. Reduced tumor 
growth and improved survival was associated with CD4+ T cells from AireGW/+ compared to WT 
donors (Figure 2A and 2B). In contrast, CD8+ T cells from AireGW/+ and WT donors had similar effects 
on tumor growth and survival (Supp. Figure 1A and B). While the absolute number of CD4+ T cells was 
not significantly increased (Figure 2C), Aire deficiency was associated with increased expression of Ki67, 
a marker of proliferation, on transferred CD4+ T cells (Figure 2D).  Neither CD8+ absolute numbers nor 
Ki67 expression, however, was increased with Aire deficiency (Supp. Figure 1C and D). These data 
suggest the possibility that CD4+ T cells may mediate enhanced melanoma rejection in Aire deficiency. 
Although CD8+ T cells are recognized as a T cell subset capable of killing cancer cells, CD4+ T 
cells also possess direct cytolytic capacity against tumors (256;257). In particular, CD4+ T cells marked 
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by Killer cell lectin-like receptor subfamily G member 1 (KLRG1) express high levels of cytotoxicity-
associated genes (258). Interestingly, frequency of KLRG1+ tumor infiltrating lymphocytes (TILs) was 
increased in recipients of CD4+ T cells from AireGW/+ compared to WT donors (Figure 2E, top). 
Additionally, the frequency of TILs expressing the cytolytic protein, granzyme B, was increased in 
recipients of CD4+ T cells from AireGW/+ compared to WT donors (Figure 2E, bottom). To test whether 
Aire-deficient CD4+ T cells have increased cytolytic capacity, we incubated purified AireGW/+ or WT 
CD4+ splenocytes with Cell-Trace Violet (CTV)-labeled B16 melanoma cell targets. A greater loss of 
B16 cells occurred with AireGW/+ compared to WT CD4+ T cells (Figure 2F). Similar numbers of B16 
cells remained, on the other hand, after incubation with AireGW/+ and WT non-CD4+ T cells (Supp. 
Figure 1E). Increased B16 cytolysis by AireGW/+ CD4+ T cells is mediated by granzyme, since addition 
of a granzyme inhibitor (3,4 dichloroisocoumarin) abrogated this effect (Figure 2G). Together, these 
findings suggest a critical role for cytolytic CD4+ T cells in mediating the enhanced melanoma rejection 
associated with Aire deficiency. 
Additive effect of Aire deficiency and anti-CTLA-4 antibody on CD4+ T cell responses. We 
next examined the T cell response in AireGW/+ mice treated with aCTLA-4 antibody. The frequency of 
Ki67+ CD4+ TILs was highest in AireGW/+ mice treated with aCTLA-4 antibody, compared to isotype 
control-treated AireGW/+ mice or aCTLA-4 antibody treated WT mice (Figure 3A), which suggests that 
Aire deficiency and aCTLA-4 antibody cooperate to increase TIL proliferation. Furthermore, frequency 
of CD4+ T cells expressing markers associated with cytolytic activity (KLRG1, granzyme B) were also 
highest in AireGW/+ mice treated with aCTLA-4 antibody (Figure 3B). Among CD8+ T cells, Aire 
deficiency and aCTLA-4 antibody did not have additive effects in increasing the frequency of Ki67+ or 
KLRG1+ cells (Supp. Figure 2). In aCTLA-4 antibody treated mice, Aire deficiency increased the 
frequency of Granzyme B+ CD8+ T cells; notably, however, in all groups, the frequency of Granzyme B+ 
cells among CD8+ T cells was quite low (<2% on average). In sum, these findings suggest that Aire 
deficiency and CTLA-4 blockade have additive effects primarily through activating CD4+ T cells. 
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 Interestingly, aCTLA-4 antibody administration in AireGW/+ mice increased the frequency of 
splenic as well as tumor-infiltrating CD4+FOXP3+ regulatory T cells (Tregs) (Supp. Figure 3A-D). 
Furthermore, the ratio of effector-to-regulatory T cells (Teff:Treg) was similar, or lower, in Aire-deficient 
mice treated with aCTLA-4 antibody for both CD4+CD25− Teff cells and CD8+ Teff cells (Supp. Figure 
3E, F). Thus, depletion of Tregs does not underlie the additive anti-melanoma effect of Aire deficiency 
and CTLA-4 blockade.  
Aire deficiency enhances anti-melanoma effects of CTLA-4 blockade in a CD4+ TCR Tg 
mouse model. We have previously reported that the self/melanoma antigen TRP-1 is expressed in the 
thymus under the control of Aire (245). We therefore sought to determine whether TRP-1 specific T cells 
might underlie the additive anti-melanoma effects of Aire deficiency and CTLA-4 blockade. To 
determine the antigen-specificity of activated cells, we used an IL-2 ELISPOT assay to detect rare 
antigen-specific T cells in the spleen of melanoma-bearing mice. As expected, Aire deficiency, with or 
without aCTLA-4 antibody administration, did not affect the frequency of IL-2 producing T cells reactive 
against the irrelevant foreign antigen, Ovalbumin (OVA, Figure 3C, left). In contrast, Aire-deficient mice 
treated with isotype control antibody harbored an expanded population of IL-2 producing T cells reactive 
against TRP-1. Moreover, aCTLA-4 antibody treatment of Aire-deficient mice further expanded the 
precursor frequency of IL-2 producing T cells reactive against TRP-1 (Figure 3C, right). Thus, increased 
melanoma rejection in AireGW/+ mice treated with aCTLA-4 antibody is accompanied by expansion of T 
cells recognizing TRP-1 self/melanoma antigen. 
Given this finding, we used a CD4+ TCR Tg model to test whether CD4+ T cells reactive against 
TRP-1 may mediate the additive effects of blocking Aire and CTLA-4 in combination. TRP-1 T cell 
receptor (TCR) Transgenic (Tg) mice are an MHCII restricted mouse model in which CD4+ T cells 
recognize the melanoma antigen TRP-1 (259).  In Aire sufficient (WT) TRP1-TCR Tg mice challenged 
with B16 melanoma, aCTLA-4 antibody administration did not affect melanoma growth or host survival 
(Figure 4A, B). In AireGW/+ TRP1-TCR Tg littermates, on the other hand, aCTLA-4 antibody 
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completely prevented tumor growth, with survival of all mice up to 50 days after tumor inoculation. 
These findings suggest that TRP-1 specific CD4+ T cells may mediate the additive anti-melanoma effects 
of Aire deficiency and aCTLA-4 antibody administration in combination.  
Vitiligo is a T cell-mediated autoimmune condition associated with effective melanoma 
immunotherapy (260). Notably, peri-orbital and tail vitiligo (Figure 4C) was observed in AireGW/+ TRP-
1 TCR Tg mice treated with aCTLA-4 antibody, reminiscent of epidermal vitiligo described in (261). 
These findings provide evidence that Aire deficiency and CTLA-4 blockade also have additive effects in 
autoimmune destruction of melanocytes. 
aCTLA-4 antibody does not impair thymic negative selection of TRP-1 TCR Tg T cells. In our 
working model, we hypothesize that Aire deficiency and aCTLA-4 antibody have additive anti-melanoma 
effects due to their function at distinct sites. Whereas Aire functions in the thymus, aCTLA-4 antibody 
functions in the immune periphery. However, it is possible that this model is incorrect and that anti-
CTLA-4 may also function through altering thymocyte development. To test this possibility, we treated 
TRP-1 TCR Tg mice with either isotype control or aCTLA-4 antibody. TRP-1 TCR Tg CD4 single 
positive (CD4SP) T cells undergo negative selection in an Aire-dependent manner (245) and therefore can 
be used to assess aCTLA-4 antibody effects. As expected, Aire deficiency results in defective negative 
selection, as demonstrated by the increased %CD4SP cells in thymi of AireGW/+ mice compared to WT 
(Supp. Figure 4). In contrast, no change in %CD4SP was seen between aCTLA-4 and isotype control 
antibody treatment in WT thymi. These findings suggest that CTLA-4 blockade does not inhibit thymic 
negative selection of melanoma-reactive CD4+ T cells.  Instead, aCTLA-4 antibody may be functioning 
in an extrathymic manner to enhance anti-melanoma immunity. 
Aire deficiency does not exacerbate colitis severity in aCTLA-4 antibody treated mice. Immune-
related colitis is a frequent ipilimumab-mediated toxicity in metastatic melanoma patients and can be life-
threatening (236;262). Likewise in mice, intestinal mucosal inflammation in experimental autoimmune 
colitis is exacerbated by aCTLA-4 antibody administration (263). Whether Aire deficiency promotes the 
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colitogenic effects of CTLA-4 blockade, however, is not known.  This question is of direct clinical 
relevance because exacerbation of immune-mediated adverse events is a potential limiting factor in 
combining CTLA-4 blockade with additional immune modulating therapies.  
We utilized an autoimmune colitis model induced by adoptive transfer of naïve T cells into 
RAG−/− recipients (264) to test the combinatorial effects of Aire deficiency and CTLA-4 blockade on 
colitis severity.  Naïve CD4+ (CD25− CD45RBhigh) effector T cells from WT or AireGW/+ mice were 
transferred into RAG-/- mice, and reconstituted recipients were treated with aCTLA-4 or isotype control 
antibody. As expected based on prior studies (263), aCTLA-4 antibody treatment of recipients 
reconstituted with WT cells resulted in more severe weight loss compared to no treatment or isotype 
control antibody (Figure 5A). Consistent with this finding, aCTLA-4 antibody administration was 
associated with more severe colonic inflammation by histological evaluation than control treatment in 
recipients of WT cells (Figure 5B and C). Importantly, weight loss and colonic inflammation was not 
exacerbated by Aire deficiency in donors, even if recipients were treated with anti-CTLA-4 antibody. 
Thus, in this model of immune-mediated colitis, Aire deficiency does not exacerbate the colitogenic 
effects of aCTLA-4 antibody treatment. This finding is consistent with previous studies reporting that 
Aire does not regulate development of colitogenic T cells (265;266).  
Anti-RANKL antibody enhances the immunotherapeutic effects of checkpoint inhibition in 
melanoma-bearing mice. mTEC survival and Aire expression are dependent on RANKL signaling, so 
that RANKL blockade with anti-RANKL (aRANKL) antibody depletes Aire-expressing mTECs in adult 
mice (249). This loss of Aire+ mTECS is associated with rescue of TRP-1 specific CD4+ T cells from 
negative selection in the thymus (Supp. Figure 5). aRANKL antibody thus represents a pharmacologic 
means to induce transient Aire deficiency through Aire-expressing mTEC depletion. Since anti-tumor 
effects of checkpoint inhibition could be enhanced by genetic Aire deficiency, we tested the effects of 
concurrent administration of aRANKL and aCTLA-4 antibodies on anti-melanoma immunity. This 
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treatment combination is clinically appealing since aRANKL antibody is FDA-approved for bone 
metastases, osteoporosis, and other indications, so has a well-known safety profile (267). 
Treatment with aRANKL and/or aCTLA-4 antibodies, however, did not have additive effects on 
improving survival in melanoma-bearing C57BL/6 polyclonal mice (data not shown). Previous studies 
have shown that vaccination with B16-GM-CSF (GVAX) potentiates anti-B16 melanoma immune 
response through activation of innate immune cells and enhancing presentation of tumor antigens to T 
cells (253;268). Furthermore, addition of GM-CSF secreting tumor vaccine to CTLA-4 blockade results 
in longer overall survival in patients with metastatic melanoma (250). We therefore utilized GVAX-
vaccinated C57BL/6 mice to evaluate the effects of aRANKL and aCTLA-4 antibodies (Figure 6A). 
C57BL/6 polyclonal mice were administered aRANKL or isotype control antibody and challenged with 2 
x 104 B16 melanoma cells. At days 3, 6, and 10 following melanoma inoculation, mice were treated with 
aCTLA-4 antibody/GVAX or GVAX alone. As expected from prior reports (253), aCTLA-4 
antibody/GVAX combination therapy was more effective than GVAX alone in prolonging host survival 
(Figure 6B). Of note, combination therapy with aRANKL/aCTLA-4 antibody/GVAX significantly 
improved host survival compared to isotype control/aCTLA-4 antibody/GVAX therapy or aRANKL 
antibody/GVAX (Figure 6B). This suggests that, in the context of GVAX, aRANKL antibody and 
aCTLA-4 antibody have additive effects in improving host survival in response to melanoma challenge. 
To assess treatment effects on CD4+ T cells, we analyzed CD4+ TILs in GVAX treated mice. 
Mice received either anti-RANKL or isotype control antibody, were inoculated with 105 B16 melanoma 
cells, and then received either anti-CTLA-4/GVAX or isotype control/GVAX. The frequency of 
Ki67+CD4+ T cells was significantly higher with aRANKL/aCTLA4/GVAX, compared to iso/aCTLA-
4/GVAX therapy (Figure 6C). Additionally, the frequency of KLRG1+ and Granzyme B+ CD4+ T cells 
was increased in the aRANKL/aCTLA4/GVAX-treated compared to the control groups (Figure 6D). 
These findings indicate that aRANKL and aCTLA4 antibodies cooperate to increase the frequency of 
tumor-infiltrating CD4+ T cells expressing cytolytic markers.   
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Discussion 
We report here that genetic Aire mutations in mice and protective Aire SNPs in humans are 
associated with increased efficacy of aCTLA-4 antibody. Additionally, we report that pharmacologic 
inhibition of Aire function with aRANKL antibody is sufficient to enhance the effects of CTLA-4 
checkpoint inhibition. Findings in this paper suggest a model (Supp. Figure 6) in which Aire normally 
purges self/melanoma antigen-reactive CD4+ T cells in the thymus, which limits the number of 
self/melanoma antigen-reactive CD4+ T cells available for peripheral activation by checkpoint inhibition. 
Genetic Aire deficiency or aRANKL antibody administration allows self/melanoma reactive T cells to 
escape negative selection in the thymus, and the increased pool of self/melanoma-reactive T cells 
available for targeting by aCTLA-4 antibody enhances the efficacy of CTLA-4 blockade in immune 
rejection of melanoma. 
In addition to aRANKL antibody, another therapeutic approach to increasing the pool of 
self/melanoma-reactive T cells in the periphery is through adoptive cellular transfer of self/melanoma-
reactive T cells. Indeed, ex vivo expansion and reinfusion of T cells specific for self/melanoma antigens 
have beneficial effect for some patients who fail conventional therapy (257;269). Of note, recent reports 
have demonstrated increased efficacy of adoptive cellular transfer when combined with aCTLA-4 
antibody (270;270). These findings provide additional supportive evidence that repopulating the periphery 
with self/melanoma reactive T cells enhances the effects of CTLA-4 blockade. Anti-RANKL antibody 
administration provides the advantage of being a relatively straightforward therapy when compared to 
adoptive cellular transfer, so may be simpler to adapt to the clinical setting. Importantly, our data 
demonstrate the effects of anti-RANKL antibody prior to B16 inoculation. The effect of anti-RANKL 
antibody on already-established tumors will be the focus of future studies. 
Anti-CTLA-4 antibody treatment has been reported to have pleiotropic effects on T cells, which 
include intratumoral Treg depletion and promoting increased Teff:Treg ratios (252;256;271;272). 
Interestingly, however, Aire deficiency and CTLA-4 blockade in combination did not result in 
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intratumoral Treg depletion in our studies. Instead, decreased melanoma growth with Aire deficiency and 
CTLA-4 blockade was associated with increased intratumoral CD4+ T cell KLRG1 expression, and 
cytolytic protein expression. These findings add to recent reports that CD4+ T cells have direct anti-tumor 
effect, especially if clonally expanded (256;273), and that aCTLA-4 antibody treatment activates tumor-
reactive cytotoxic CD4+ T cells (274).  
CTLA-4 blockade is associated with colitis and other immune related adverse events (236;262). 
This finding is not surprising since genetic deficiency of CTLA-4 in mice results in lymphoproliferation 
and multiple autoimmune manifestations (275;276). Colitis can be life threatening and is the most 
common ipilimumab related toxicity in metastatic melanoma patients. Therefore, it is important to 
consider whether potential treatment modalities to be used in combination with CTLA-4 blockade will 
exacerbate colitis. We show in this study that lack of Aire function does not add to the severity of colitis 
in anti-CTLA-4 antibody treated hosts. This result may seem unexpected since Aire has a well-known 
role in preventing organ-specific autoimmune disease (277). Previous studies, however, have also 
reported that Aire does not regulate colitogenic T cell development (265;266), possibly because 
colitogenic T cells may be directed against non-self proteins such as colonic microbiota antigens. Thus, 
combination of central tolerance blockade and checkpoint inhibition may improve therapeutic index, 
compared to checkpoint inhibition alone. 
 Anti-RANKL antibody represents a pharmacologic means to block central tolerance and can 
enhance the effects of checkpoint inhibitors in mice. In addition to its role in mTEC development, 
RANKL has a well-recognized role in the development, function, and survival of osteoclasts (278). For 
these effects, aRANKL antibody (denosumab) is FDA approved for treatment of osteoporosis in 
postmenopausal women (279) and other bone-related diseases (267). There is therefore substantial 
clinical experience with aRANKL antibody in patients, which should facilitate clinical testing to 
repurpose aRANKL antibody as an immunotherapy for the treatment of metastatic melanoma. Because 
the thymus involutes with age, whether thymus output can be manipulated in adults for therapeutic 
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purpose is an open question. The median age at diagnosis of melanoma is 59 years, when thymic function 
is often assumed to be minimal. Multiple studies in mice and humans suggest that thymic function 
remains active in adults. Thymic output has been reported to continue in aged mice (280) and thymic 
function is measurable in adult humans up to age 76 (281). Our data that aRANKL antibody increases 
thymic output of TRP-1 specific T cells in adult mice [Supp. Figure 5 and (249)] supports the possibility 
that thymus function can be altered for therapeutic purpose in adults. Of note, a case report of a patient 
with metastatic melanoma who was concomitantly treated with anti-RANKL and anti-CTLA-4 antibodies 
also supports further study of this combination therapy (282). 
Finally, checkpoint inhibitors have been shown to have a therapeutic effect in a number of 
different cancers, including prostate and renal cancer (283). Thus, central tolerance blockade by aRANKL 
as a strategy to enhance the efficacy of checkpoint inhibition may be relevant in multiple cancer settings. 
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Materials and Methods 
Mice. C57BL/6 AireGW/+ mice (251) and C57BL/6 AireGW/+ TRP-1 TCR Tg RAG−/− mice 
(245) were housed and bred in sterile, specific pathogen-free mouse facilities at the University of North 
Carolina at Chapel Hill (UNC-CH) and University of California, San Francisco (USCF). C57BL/6 Aire 
wild-type (WT) littermate controls were used in all experiments. Recombination activating gene 
(RAG1)−/− mice were purchased from the Jackson Laboratory.  
Antibodies and Flow cytometry. Anti-CD4 (clone RM4-5), anti-CD3 (clone 145-2c11), anti-
Ki67 (clone SolA15), anti-KLRG1 (clone 2F1), anti- Granzyme B (clone NGZB), anti-FOXP3 (clone 
FJK-16s), and anti-CD25 (clone PC61.5) antibodies were purchased from eBioscience. Anti-CD8a (clone 
5H10) antibody was purchased from Invitrogen. Intracellular staining for cytokines and FOXP3 were 
performed as in (245). All samples were run on a Dako CyAn flow cytometer (Beckman-Coulter) and 
analyzed using FlowJo (TreeStar).  
Isolation of tumor-infiltrating lymphocytes. Tumor-infiltrating lymphocytes (TIL) were 
isolated as previously described (245). Tumors were dissected and minced before incubation with 
collagenase type I/IV and DNase I. Lymphocytes were then enriched on Percoll density gradient prior to 
flow cytometric analysis. 
B16 melanoma and antibody administration. B16-F10 is a TRP-1-expressing C57BL/6-
derived spontaneous melanoma cell line originally purchased from the American Tissue Culture 
Condition. B16 melanoma cells were cultured as described in (284). Mice were injected subcutaneously 
with 1×105 B16 melanoma cells as in (245). Tumor measurements and survival were determined as 
described in (249). 
For immunotherapy experiments, anti-CTLA-4 monoclonal antibody (mAb; clone 9D9; 100 
μg/mouse, BioXcell) or IgG isotype control antibody (clone MPC-11; 100 μg/mouse, BioXcell) were 
injected intraperitoneally (i.p.) on days 3, 6 and 9 following B16 melanoma cell injection as described in 
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(52). For combination antibody administration experiments, anti-RANKL antibody (clone IKK22/5; 100 
μg/mouse, BioXcell) or isotype control antibody (clone 2A3; 100 μg/mouse, BioXcell) was injected every 
other day for a total of six doses. 19 days following treatment initiation, mice were subcutaneously 
injected with 2x104 B16-F10 melanoma cells for survival analysis and 1x105 for immune-phenotyping. 
On days 3, 6, and 10 following melanoma inoculations, anti-CTLA-4 antibody/GVAX therapy was 
administered as described in (253). 
Adoptive transfer of magnetically isolated (using Miltenyi Biotec beads) CD4+ and CD8+ T cells 
from spleen of WT and AireGW/+ mice were performed in a 1:1 donor:recipient ratio into C57BL/6 
RAG−/− recipients using retro-orbital intravenous (i.v.) route of injection. After 7 days, recipients were 
injected subcutaneously with 1×105 B16-F10 melanoma cells. Tumor growth, survival, and development 
of vitiligo were monitored daily.  
In vitro B16 cytotoxicity assay. Splenocytes from WT and AireGW/+ melanoma-bearing 
C57BL/6 mice were purified using CD4 beads (Miltenyi Biotec) and cultured in vitro with 5 µg/ml TRP-
1 peptide at 37°C. Following overnight incubation, peptide-primed CD4+ and non-CD4+ T cells were 
harvested and used for in vitro cytotoxicity assay with B16-F10 melanoma cells. To determine in vitro 
killing of tumor targets, B16 cells were loaded with 0.5 mM Cell-Trace Violet and co-incubated for 12-14 
hrs with peptide-primed CD4+ and non-CD4+ cells. Proliferation of Cell-Trace Violet B16 cells was 
analyzed by flow cytometry and quantified using CountBright© Absolute counting beads (Thermo-Fisher 
Scientific). 3, 4 Dichloroisocoumarin; a serine protease inhibitor (Enzo Life Sciences; 25 μM) was used 
for pan-granzyme inhibition.  
In vitro IL-2 ELISPOT assay.  ELISPOT assays for IL-2 release (BD Biosciences) were 
performed on splenic CD4+ CD25− effector T (Teff) cells from B16-F10 tumor-bearing C57BL/6 WT or 
AireGW/+ mice. CD4+ CD25− Teff cells were enriched by magnetic beads (Miltenyi Biotec).  5×105 
cells were plated for 20-22 hours on 96-well plates, which had been pre-coated with anti-mouse purified 
IL-2 antibody overnight. Cells were left unstimulated in media (negative control) or stimulated with 
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PMA-Ionomycin (positive control). Cells were incubated in separate wells with 5 µg/ml of TRP1 
(NCGTCRPGWRGAACNQKILTVR) purchased from Genemed Synthesis Inc. and OVA 
(ISQAVHAAHAEINEAGR) peptides purchased from InvivoGen. Culturing of the plates, washing, and 
counterstaining were performed according to manufacturers’ instructions. Visualization and analysis of 
the spots were performed on the ImmunoSpot counter (Cellular Technology Ltd). IL-2 response of 
stimulated cultures was calculated by subtracting the number of spot-forming colonies in the negative 
unstimulated control from the number of spot forming colonies in the wells stimulated by peptides/5×105 
cells. 
Single Nucleotide Polymorphism (SNP) Genotyping. Peripheral blood mononuclear cells 
(PBMC) collected as part of the ECOG-ACRIN Cancer Research Group study E1608 (250) were kindly 
provided by the ECOG-ACRIN Central Biorepository and Pathology Facility. Following DNA extraction 
from PBMC, SNP genotyping assays (Applied Biosystems Taqman) were performed by the UNC-CH 
Mammalian Genotyping Core for the following SNPs of the Aire gene: rs1800522/rs1133779, rs2075876, 
rs56393821, rs1800520, and rs1055311. Genotyping for rs1055311 was confirmed by Sanger sequencing 
using two primers flanking exon 6 of the Aire gene (Forward sequence: 5'-
GAATGCAGGCTGTGGGAACT-3’; Reverse sequence: 5’-AAGAGGGGCGTCAGCAATG-3’; product 
size 441bp).  
Experimental Colitis. CD4+ cells were enriched from WT and AireGW/+ female donor spleens 
using the CD4+ T cell Isolation Kit II (Miltenyi Biotec) according to manufacturer instructions. Cells 
were labeled and sorted for CD4+ CD25- CD45RBhi cells by fluorescence-activated cell sorting, as 
previously described (285). 5×105 cells were injected i.p. into 4-7 week old RAG-/- recipient mice. 3 
days after transfer, recipient mice were injected i.p. with 100μg of isotype (clone MPC-11, BioXCell) or 
anti-CTLA4 (clone 9D9, BioXCell) antibody at 3-day intervals. Weights were measured weekly from 
initial cell transfer. Lack of survival was defined as death or weight loss >20%. 
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Colon Histopathology. Colons were harvested at 10 weeks after adoptive transfer or earlier if 
weight loss of 20% was noted. Specimens were fixed in 10% formalin, sectioned (5 microns) and stained 
with Hematoxylin and Eosin. Scoring for inflammation was performed as described (286;287).  
Statistics. R, PRISM 5.0 (GraphPad Software, Inc.) and Microsoft Office Excel software (2013) 
were used to analyze data. T-tests were used to compare differences between 2 groups. One-way ANOVA 
and t-tests with p-values adjusted using Hommel’s correction for multiple comparisons (288) were used 
to compare differences between more than 2 groups. Survival curves were compared by Mann-Whitney 
U-test. P-values of <0.05 were considered significant. 
Study approval. Study approval for human samples was obtained from the ECOG Laboratory 
Science & Pathology, and Executive Review Committees. All animal studies were approved by the 
Animal Care and Use Committees at UNC-CH and UCSF. 
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Figure 1: Association between Aire and anti-melanoma effects of CTLA-4 blockade in mice and 
humans. A and B) WT and AireGW/+ mice were s.c. injected with 105 B16 melanoma cells followed by 
anti-CTLA-4 (aCTLA-4) antibody or isotype control (iso) antibody treatment. Mice in each group were 
followed for B16 melanoma tumor growth and survival. n=7-12 per group, cumulative of at least 2 
independent experiments. *p<0.05. C and D) Comparison of progression-free survival (PFS) and overall 
survival (OS) probability between patients with Aire SNP rs1055311 (TT versus CT/CC). 
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Figure 2: Aire deficiency increases CD4+ T cell cytolytic function to reduce melanoma growth. 
CD4+ splenocytes were transferred from WT and AireGW/+ donors into RAG-/- recipients, followed by 
subcutaneous B16 melanoma injection on Day 7. Recipients were followed for tumor growth and 
survival. A and B) B16 melanoma tumor growth and survival was measured after B16 inoculation in 
recipients; n=15 per group, *p<0.05. **p<0.01. C-E) Tumor-infiltrating lymphocytes (TIL) were 
harvested on Day 19 following B16 melanoma inoculation in recipients of either WT or AireGW/+ CD4+ 
splenocytes. Absolute numbers of CD4+ tumor-infiltrating cells are shown in (C). ns=not significant. 
Representative flow cytometry plots and average cumulative frequencies of Ki67+ (D), KLRG1+ and 
Granzyme B+ (E), among CD4+ T cells. *p<0.05, **p<0.01. F) Representative flow cytometry histograms 
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and average absolute cell trace violet-labeled B16 cell numbers after co-incubation with WT and AireGW/+ 
CD4+ T cells. G) Average relative B16 cell numbers after co-incubation with CD4+ T cells from WT and 
AireGW/+ mice along with pan-granzyme inhibitor (3, 4 Dichloroisocoumarin). 
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Figure 3: Additive effect of Aire deficiency and anti-CTLA-4 antibody on T cell responses. A-B) 
Tumor-infiltrating lymphocytes (TIL) were harvested on Day 19 following B16 melanoma inoculation in 
WT and AireGW/+ mice treated with aCTLA-4 or iso antibody. Representative flow cytometry plots and 
average cumulative frequencies of Ki67+ (A), KLRG1+ and Granzyme B+ (B) among CD4+ T cells. n=9-
12 in each group, *p<0.05, 727 **p<0.01. C) ELISPOT with splenocytes harvested on Day 14 following 
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B16 melanoma inoculation in WT and AireGW/+ mice treated with anti-CTLA-4 antibody (aCTLA-4) or 
isotype control antibody (iso). Cumulative spot forming cells (SFC)/5×105 cells secreting IL-2 with OVA 
and TRP-1 was analyzed. Each data point represents an individual animal. *p<0.05, n.s=not significant. 
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Figure 4: Additive anti-melanoma effect of Aire deficiency and anti-CTLA-4 antibody in TRP-1 
CD4+ TCR Tg mice. A and B) Aire sufficient (WT) and AireGW/+ TRP-1 TCR Tg mice were s.c. injected 
with 105 B16 melanoma cells followed by anti-CTLA-4 antibody (aCTLA-4) or isotype control antibody 
(Iso) treatment, as outlined. Mice in each group were followed for B16 melanoma tumor growth (A) and 
survival (B). n=7-12 per group, cumulative of at least 2 independent experiments. *p<0.05. C) Examples 
of periporbital and tail vitiligo in AireGW/+ mice treated with anti-CTLA-4 antibody. 
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Figure 5: Aire deficiency does not exacerbate the development of experimental autoimmune colitis 
associated with anti-CTLA4 antibody treatment. A) Percent initial body weight of RAG-/- recipients 
after transfer of WT or AireGW/+ CD4+ CD25- CD45RBhi splenocytes. After transfer, recipients were 
treated with anti-CTLA-4 antibody (aCTLA4), untreated, or treated with isotype control antibody (iso). 
Cumulative data from two independent experiments are shown. *p<0.05 comparing anti-CTLA-4 
antibody treatment versus untreated/isotype control antibody treatment in recipients of WT cells. n.s.=not 
significant. B) Representative Hematoxylin and Eosin stained sections of descending colons and C) 
average histopathological scores of colons from recipients of CD4+ CD25- CD45RBhi splenocytes derived 
from WT and AireGW/+ mice and administered aCTLA-4 or untreated/isotype control antibody (-). Gray 
arrowheads = immune cell infiltration in lamina propria; black arrowheads = immune cell infiltration in 
the submucosa. *p<0.05; n.s.=not significant. 
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Figure 6: Combination aRANKL and aCTLA-4 antibody administration enhances immune 
rejection of melanoma. A) Schematic of treatment regimen, in which anti-RANKL (aRANKL) or 
isotype control (iso) antibody was injected every other day for 11 days, followed by s.c. B16 melanoma 
injection (2x104 cells) on Day 18. GVAX with or without anti-CTLA-4 antibody was given on days 3, 6, 
and 10 following melanoma injection. B) Survival curves in GVAX treated mice receiving indicated 
combinations of therapy. n=10 for each group. *p<0.05. Tumor-infiltrating lymphocytes (TIL) were 
harvested on Day 19 following 105 B16 melanoma cell inoculation. Representative flow cytometry plots 
100 
 
and average cumulative frequencies of Ki67+ (C), KLRG1+ and Granzyme B+ (D) among CD4+ T cells 
was measured. n=9-12 in each group, *p<0.05, **p<0.01. ***p<0001. 
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Supplementary Figure 1: Aire deficiency has minimal effects on CD8+ T cell cytolytic function in 
melanoma bearing mice. A and B) RAG-/- recipients of CD8+ T cells from WT and AireGW/+ mice were 
followed for B16 melanoma tumor growth and survival after B16 inoculation; n=10 per group, Mann 
Whitney U-test.  *p<0.05, n.s.=non-significant. C) Absolute numbers of CD8+ tumor-infiltrating cells. t-
test. ns=not significant. D) Average cumulative frequencies of Ki67+ among CD8+ T cells. Tumor-
infiltrating lymphocytes (TIL) were harvested on Day 19 following B16 melanoma inoculation in RAG-/- 
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recipients of CD8+ T cells from WT and AireGW/+ donor mice. t-test. ns=not significant. E) Representative 
flow cytometry histogram comparison and average absolute B16 cell numbers of cell trace violet-labeled 
B16 cells after co-incubation with non-CD4+ T cells from WT and AireGW/+ mice. t-test. ns=not 
significant. 
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Supplementary Figure 2: Modest effect of Aire deficiency and anti-CTLA-4 antibody on CD8+ T 
cell responses. Tumor-infiltrating lymphocytes (TIL) were harvested on Day 19 following B16 
melanoma inoculation in WT and AireGW/+ mice treated with aCTLA-4 or iso antibody. Representative 
flow cytometry plots and average cumulative frequencies of Ki67+, KLRG1+, and Granzyme B+ among 
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CD8+ T cells. n=9-12 in each group. One-way ANOVA with Tukey’s multiple comparisons test. ns=not 
significant, *p<0.05. 
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Supplementary Figure 3: Anti-CTLA-4 antibody treatment in Aire deficient mice does not decrease 
Treg population. Splenocytes and tumor-infiltrating lymphocytes (TIL) were harvested on Day 19 
following B16 melanoma inoculation in WT and AireGW/+ mice treated with anti-CTLA-4 antibody 
(aCTLA-4) or isotype control antibody (Iso). A) Representative flow cytometry plots of FOXP3 and 
CD25 expression and (B) average cumulative frequencies of FOXP3+ Tregs within CD4+ splenocyte 
population. C) Representative flow cytometry plots of FOXP3 and CD25 expression and (D) average 
cumulative frequencies of FOXP3+ Tregs within CD4+ TIL population. E and F) Average cumulative 
ratio of CD4+ Teffs : FOXP3+ Tregs (E) and CD8+ T cells : FOXP3+ Tregs (F). One-way ANOVA with 
Tukey’s multiple comparisons test. *p<0.05, **p<0.01, n.s= not significant. 
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Supplementary Figure 4: anti-CTLA-4 antibody does not impair negative selection of TRP-1 
specific CD4+ T cells. A) Representative flow cytometric plots of CD4+ and CD8+ thymocytes from 
AireGW/+ or WT TRP-1 TCR Tg mice. WT TRP-1 TCR Tg were treated with either isotype control 
antibody (iso) or anti-CTLA-4 antibody (aCTLA-4). B) Cumulative frequency (mean +/- SD) of CD4 
single positive (SP) cells. One-way ANOVA with Tukey’s multiple comparisons test. *p<.05. n.s.=not 
significant. 
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Supplementary Figure 5: anti-RANKL antibody impairs negative selection of TRP-1 specific CD4+ 
single positive T cells. Representative flow cytometric plots of CD4+ and CD8+ thymocytes from TRP-1 
TCR Tg mice treated with isotype control antibody (iso) or anti-RANKL antibody (aRANKL). Mean +/- 
SD shown. t-test. **p<.01. 
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Supplementary Figure 6: Model of mechanism underlying additive anti-melanoma effects of 
combination central and peripheral tolerance blockade. A) In the thymus, Aire in mTECs promotes 
self/melanoma antigen expression, which results in negative selection of self/melanoma-reactive CD4+ T 
cells. As a result, the efficacy of checkpoint inhibition is limited by the scarcity of melanoma-reactive T 
cells in the periphery. B) Aire deficiency or transient depletion of Aire-expressing mTECs with anti-
RANKL (aRANKL) antibody rescues self/melanoma antigen-reactive effector CD4+ T cells from 
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negative selection. This expansion of the melanoma-reactive T cell pool available for activation by 
checkpoint inhibitors enhances anti-melanoma immunity.  
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